面向伴侣动物(犬猫)的皮下植入式无源LC甘油三酯监测芯片
无源LC谐振传感与射频耦合读取原理(耦合建模、阻抗匹配与频移解调)
共同点:围绕无源LC谐振器在射频电感耦合链路上的物理与电路问题展开——谐振网络参数优化与耦合感知自适应、中继/负载阻抗匹配以最大化感应电流、基于谐振频率的动态前端监测、自动谐振调谐与频率可调LC结构、集成无源元件与读取电路设计、以及谐振频率扰动下的鲁棒性提升;并含一篇系统综述,指出封装、耦合距离、温漂与老化漂移等共性局限。构成芯片『无电池、隔空供电+频移读出』的链路层基础,并给出长期标定与稳定性风险清单。
- Resonant Network Optimization and Coupling-Aware Adaptive BPSK Design for High-Speed Inductive Data Links(Yunfang Zhang, Yang Zhao, Yong Lian, 2026, International Symposium on Circuits and Systems)
- Impedance Matching to Maximize Induced Current in Repeater of Resonant Inductive Coupling Wireless Power Transfer Systems(Masataka Ishihara, K. Umetani, E. Hiraki, 2018, European Conference on Cognitive Ergonomics)
- A Resonant-Frequency-Based Dynamic Front-End Monitoring Strategy for Series-Series-Compensated Inductive Power Transfer Systems Without Communication(Zhen Sun, Jun-Ming Zeng, Yun Yang, 2026, IEEE transactions on industry applications)
- Automatic Resonance Frequency Tuning Method for Repeater in Resonant Inductive Coupling Wireless Power Transfer Systems(Masataka Ishihara, K. Umetani, E. Hiraki, 2018, 2018 International Power Electronics Conference (IPEC-Niigata 2018 -ECCE Asia))
- Integrated passives and resonant inductive coupling as a displacement sensing mechanism for large piston/rotation micromirrors(Victor Farm-Guoo Tseng, 2015, No journal)
- A Frequency-Tunable LC Resonant Wireless Passive Temperature Sensor(Xindi An, Jiongzheng Zhang, T.-E. Shen, Qi Wen, Yu-Jian Jin, Jun-Yang Li, 2026, IEEE International Conference on Nano/Micro Engineered and Molecular Systems)
- Wireless readout circuit of passive LC resonant transducer(Jie Chen, Cong Zhang, Shuang-Ying Lei, M. Qin, 2013, No journal)
- Improving Robustness Against Variation in Resonance Frequency for Repeater of Resonant Inductive Coupling Wireless Power Transfer Systems(Masataka Ishihara, Shoma Ohata, Keita Fujiki, K. Umetani, E. Hiraki, 2018, EPE)
- Review of Research Status and Development Trends of Wireless Passive LC Resonant Sensors for Harsh Environments(Chen Li, Qiu-lin Tan, Ping-Gang Jia, Wen-Dong Zhang, Jun Liu, C. Xue, J. Xiong, 2015, Italian National Conference on Sensors)
LC微系统集成与电容式敏感结构(MEMS/CMOS、叉指电容、温度与宽禁带无电池传感)
共同点:从器件集成与敏感电容结构层面研究无源LC传感的实现方式——硅基/CMOS工艺的无源LC微系统、电感-电容谐振回路的MEMS电容式无线敏感、叉指电容作为增敏换能单元的结构参数—灵敏度规律、RFID型温度传感、以及可在高温/恶劣环境工作的宽禁带SiC无电池无线传感器,并提供典型LC结构的设计与特性表征范例。为芯片的敏感电容(酶膜介电/电容变化)设计与微纳制造工艺路线提供可移植方案。
- Silicon-Based Wireless Passive LC Microsystems with Potential for Pulmonary Artery Pressure Monitoring(Pichao Pan, Li Wang, Min Liu, Xin-Xin Li, 2025, IEEE/LEOS International Conference on Optical MEMS)
- An inductive-capacitive-circuit-based micro-electromechanical system wireless capacitive pressure sensor for avionic applications: Preliminary investigations, theoretical modelling and simulation examination of newly proposed methodology(S. Jindal, Ankush Mahajan, S. Raghuwanshi, 2019, Measurement and control (London. 1968))
- Interdigital Capacitor-Based Passive LC Resonant Sensor for Improved Moisture Sensing(K. Dimitrov, Sang-Woo Song, Hyungjun Chang, Taejun Lim, Yongshik Lee, B. Kwak, 2020, Italian National Conference on Sensors)
- RFID-Enabled Temperature Sensor(I. Abdel-Motaleb, K. Allen, 2012, No journal)
- Wireless Battery-Free SiC Sensors Operating in Harsh Environments Using Resonant Inductive Coupling(Hoang-Phuong Phan, Tuan-Khoa Nguyen, T. Dinh, Afzaal Qamar, Alan Iacopi, Jun-Wei Lu, D. Dao, M. Rais-Zadeh, Nam-trung Nguyen, 2019, IEEE Electron Device Letters)
- Design and Characteristics of a Wireless Non-enzyme Glucose Sensor Based on Resonant LC Passive Circuit(T. Pham, P. Nguyễn, Anh Van Bui, 2024, VNU Journal of Science Mathematics - Physics)
高灵敏柔性LC压力/多参数敏感结构与增敏设计
共同点:以压力、眼压、温度等物理量为模型,量化无源LC谐振器在灵敏度、耦合距离、检测限上的设计权衡——超高灵敏柔性LC压力传感、双螺旋谐振接触式传感、微加工眼压传感、双参数(压力+温度)无源传感及球面电容式谐振传感器。其灵敏度—尺寸—封装折中方法与双敏感/差分抗干扰思路,可直接迁移到『酶膜响应→谐振频移』的甘油三酯敏感结构设计。
- Wireless Passive Ultrahigh Sensitivity LC Pressure Sensor Based on Ionic Dielectric Layer for Wearable Electronics(Hai-Rong Kou, Yuzhen Wang, Yu-Hang Pang, Yu-Lei Chen, Li-Bo Yang, Xiao-Yong Zhang, Zhen-Zhen Shang, Liang Zhang, Zhi-Guo Gui, 2025, IEEE Sensors Journal)
- High-sensitivity LC wireless passive flexible pressure sensor based on anisotropically distributed nmFe with dual-sensitivity mechanism(Hang-Liang Ren, Xiaofeng Zheng, Yun-Long Zhu, Zhi-Cheng Dong, Yi Hu, Qian-Cheng Xu, Jian Li, Zhen-Yu Xue, Pei-Mei Dong, Ke Wang, Xu-Dong Cheng, 2025, Measurement science and technology)
- Highly sensitive wireless dual-spiral resonant contact lens for continuous intraocular pressure monitoring.(Ying Liu, Zhi-xian Chen, Xiaoyu Zhao, Lin Xu, Sheng-Li Mi, 2026, Lab on a Chip)
- Wireless Intraocular Pressure Sensing Using Microfabricated Minimally Invasive Flexible-Coiled LC Sensor Implant(Po-Jui Chen, Saloomeh Saati, R. Varma, M. Humayun, Yu-Chong Tai, 2010, Journal of microelectromechanical systems)
- A Wireless Passive Pressure and Temperature Sensor via a Dual LC Resonant Circuit in Harsh Environments(Qiu-lin Tan, Tao Luo, Tanyong Wei, Jun Liu, Li-Wei Lin, J. Xiong, 2017, Journal of microelectromechanical systems)
- Passive Spherical Capacitive-Based Resonant Sensor for Wireless Soil Moisture Monitoring(Sheng Ding, Qiwu Zhang, S. Roundy, Le-Ang K. Kam, C. Zesiger, D. Young, 2025, Italian National Conference on Sensors)
皮下/间质液无源无线传感的植入式可行性与在体验证
共同点:把无源LC/射频耦合原理真正落地到皮下场景——可穿透多层皮肤无线读取的电池free体腔内传感器、皮下穿孔胶囊连续监测组织液压力、绷带下柔性LC谐振器在犬类创面模型中的在体验证、射频供电的植入式葡萄糖生物传感器,以及以二极管调制无源LC标签实现深层组织标志物监测的电磁传感平台。共同证明『微创植入+隔空供能与读取+体液/生理量长期连续监测』在真实动物与人体中的工程可行性,是本项目芯片架构最接近的技术原型。
- An Electromagnetic Sensor Platform with Passive Implant-Target and Wearable Patch for Monitoring Deep-Tissue Biomarkers(Mingke Yang, Jianzheng Li, Shao-Kai Yuan, Jinghan Yao, Ziwei Liu, Ya-Jie Qin, 2025, Annual International Conference of the IEEE Engineering in Medicine and Biology Society)
- Wireless and Battery-Free Sensor for Interstitial Fluid Pressure Monitoring(Cheng-Yang Qian, Fan Ye, Jun-Ye Li, P. Tseng, M. Khine, 2024, Italian National Conference on Sensors)
- Development of a minimally invasive technique to measure the interstitial fluid pressure for remote monitoring of heart failure(H. Zafar, J. Passman, R. Sandy, C. Wright, F. Wright, H. Evans, P. Hanumapura, S. Sebastian, L. Ebah, A. Khalifa, S. Rowe, R. Schwartz, A. French, A. Rothman, 2024, European Heart Journal)
- Monitoring Wound Health through Bandages with Passive LC Resonant Sensors.(Sadaf Charkhabi, Kyle Jackson, A. Beierle, Adam R. Carr, E. Zellner, N. Reuel, 2020, ACS Sensors)
- Radio Frequency-Based Implantable Glucose Biosensor(Jinghao. Tan, 2022, International Journal of Electrochemical Science)
组织液—血液浓度相关性与分子监测模型验证(甲氨蝶呤、乳酸、乙醇、近红外多孔硅)
共同点:以具体分子为模型,论证皮下组织液浓度可替代/反映血浆浓度的前提条件与局限——ISF-血浆对应关系与组织液屏障、乳酸在ISF中的连续监测可行性、乙醇蒸气在体无线检测、免标记近红外多孔硅植入式生物传感,以及薄膜硝化纤维电致分解的原位取样/信号转换方法。为『皮下组织液甘油三酯可反映血脂水平』提供方法学依据,同时提示时间滞后、蛋白吸附与个体差异风险。
- A Minimally Invasive, Subcutaneous Biosensor Reliably Estimates Plasma Methotrexate Exposure and Quantifies Plasma-to-Tissue Transport Kinetics.(J. M. Gibson, Zeki Duman, Nicole A. Emmons, Danielle O. Sogbesan, J. Hespanha, C. Kirkpatrick, T. Kippin, K. Plaxco, 2026, ACS Pharmacology & Translational Science)
- Monitoring of Lactate in Interstitial Fluid, Saliva and Sweat by Electrochemical Biosensor: The Uncertainties of Biological Interpretation(A. Spehar-Deleze, S. Anastasova, P. Vadgama, 2021, Chemosensors)
- In vivo wireless ethanol vapor detection in the Wistar rat(C. Cheney, Bernadeta R. Srijanto, D. Hedden, A. Gehl, T. Ferrell, Jonathan A. Schultz, E. Engleman, W. J. McBride, S. O'Connor, 2009, Sensors and actuators. B, Chemical)
- Implantable, Label‐Free NIR‐Based Porous Silicon Biosensor for Monitoring Biomarkers in Interstitial Fluid(Pritam Sharma, Jann Harberts, Raquel Sánchez-Salcedo, Pouya Dehghankelishadi, N. Voelcker, 2025, Advanced Sensor Research)
- Electrically Induced Decomposition of Thin-Film Nitrocellulose Membranes for On-Demand Biosensor Activation(Benjamin Horstmann, K. Yokoyama, Ü. Özgür, V. Avrutin, 2020, SoutheastCon)
微针/导管式微创取液与长期植入器件工程(自校准、抗污损与寿命管理)
共同点:面向长期植入的器件工程问题——自校准多路复用微针电极阵列、微针电化学生物传感器进展综述、导管式电极实现连续适配体检测、可贴附兼可植入的聚合物微针、开窗式微针乳酸连续监测、中空微针PB基传感。共同解决酶降解、生物污损、信号漂移与器件寿命问题,其尺寸约束、抗污损涂层与自校准策略可直接指导本项目敏感膜寿命管理与校准流程。
- Self-calibrating multiplexed microneedle electrode array for continuous mapping of subcutaneous multi-analytes in diabetes(Xiang-Ling Li, Shantao Zheng, Mengyi He, Xin-Shuo Huang, Cheng Yang, Jing-Shan Mo, Jing-Bo Yang, Cheng-Duan Yang, Hui-jiuan Chen, Xi Xie, 2025, The Innovation)
- Progress of Microneedle Electrochemical Biosensors for Interstitial Fluid Detection and Monitoring(Xin-Xing Gong, Yeru Wen, Yimin Pang, Song Liu, Quan Yuan, 2025, Chinese journal of chemistry)
- Catheter-Electrode System for Continuous Aptamer-Based Sensing in the Rat Subcutaneous Space(John O. Mack, Yao Wu, Yu-Chan Yuan, Remy Bell, Netzahualcóyotl Arroyo-Currás, 2025, ECS Sensors Plus)
- Skin-Attachable and Implantable Polymer Microneedle Biosensor for Continuous Glucose Monitoring(Hyunsik Kim, Hyosang Yoon, Md. Sharifuzzaman, J. Park, Daeheum Kim, Jaeyeong Park, 2020, IEEE/LEOS International Conference on Optical MEMS)
- Fenestrated Microneedle Biosensor for Continuous In Vivo Lactate Monitoring in Interstitial Fluid.(Masoud Khazaei, Ali-Reza Shokouhi, P. Zangabad, V. Cadarso, Muamer Dervišević, N. Voelcker, 2026, Small)
- Vacancy-Regulated Prussian Blue-Based Hollow Microneedle Biosensor for Interface Protective Glucose Monitoring in Interstitial Fluid(Yan Chen, Hong-Ying Sun, Zhi-Yang Gu, Guo-Yue Shi, 2026, Journal of Analysis and Testing)
三联酶级联甘油三酯生化传感体系与共固定化工艺
共同点:以脂肪酶(脂蛋白脂肪酶)→甘油激酶→甘油-3-磷酸氧化酶(±过氧化物酶)级联为识别核心,研究甘油三酯的酶解、共固定化方式(如戊二醛交联于PVC条)、最适pH/温度与可重用性,以及电流型/生物电催化型传感器在血清样本中的线性范围、检出限与抗干扰性能。为本项目敏感膜的酶体系组成、固定化工艺与定量标定提供最直接依据。
- Covalent immobilization of lipase, glycerol kinase, glycerol-3-phosphate oxidase & horseradish peroxidase onto plasticized polyvinyl chloride (PVC) strip & its application in serum triglyceride determination(N. Chauhan, J. Narang, C. Pundir, 2014, The Indian journal of medical research)
- An improved amperometric triglyceride biosensor based on co-immobilization of nanoparticles of lipase, glycerol kinase and glycerol 3-phosphate oxidase onto pencil graphite electrode.(Vinay Narwal, C. Pundir, 2017, Enzyme and Microbial Technology)
- Amperometric triglyceride bionanosensor based on nanoparticles of lipase, glycerol kinase, glycerol-3-phosphate oxidase.(C. Pundir, V. Aggarwal, 2017, Analytical Biochemistry)
- An Enhanced Amperometric Triglyceride Biosensor by Graphene Oxide Nanoparticles(C. S. Pundir, Vinay Narwal, Parveen Kumar, Deepa, 2025, International Journal of Applied Sciences and Biotechnology)
- Bioelectrocatalytic sensor for triglycerides in human skin sebum based on enzymatic cascade reaction of lipase, glycerol kinase and glycerophosphate oxidase.(Chi Yong Jeong, Yong D. Han, Jae Ho Yoon, H. Yoon, 2014, Journal of Biotechnology)
多酶级联定向组装与纳米/电极界面信号增效
共同点:聚焦提升级联效率与信号转换增益的通用策略——多酶级联的空间定位组装以缩短中间产物扩散距离、纳米颗粒平台的理性设计以放大催化/电学响应、叉指电极酶传感器构型优化。为将三联酶级联产物(H2O2/酸化/介电变化)高效转换为可被LC前端量化的电学或介电偏移提供技术选项。
- Positional assembly of multi-enzyme cascade reaction in polyelectrolyte doped microcapsule through electrospray and layer-by-layer assembly(Shiyi Che, Jie Wang, Xiao-Yuan Ji, Z. Su, Shao-Min Wang, Song-Ping Zhang, 2020, Synthetic and Systems Biotechnology)
- Rational Design of Nanoparticle Platforms for "Cutting-the-Fat": Covalent Immobilization of Lipase, Glycerol Kinase, and Glycerol-3-Phosphate Oxidase on Metal Nanoparticles.(V. Aggarwal, C. Pundir, 2016, Methods in Enzymology)
- Development of Interdigitated Electrode Based Enzyme Sensor for Triglyceride Monitoring Using Engineered Oxygen Insensitive Glycerol 3-Phosphate Oxidase(Inyoung Lee, Sheng-Fu Tong, Mika Hatada, Adrianna N. Masterson, K. Hiraka, J. Okuda-Shimazaki, W. Tsugawa, Gary Hughes, K. Sode, 2023, Social Science Research Network)
丝素蛋白水凝胶作为酶固定基质与多酶共固定微环境
共同点:以丝素蛋白为核心材料,通过盐驱动自组装/机械研磨纳米纤维等无溶剂或温和工艺实现多酶在同一蛋白基质中的共包埋与级联化学计量比调控,并显著提升操作稳定性、热稳定性与储存寿命;同时包括丝素水凝胶与石墨烯/场效应器件的封装集成案例。构成敏感膜『生物相容、可降解、可长期保持酶活』的材料学依据,并给出酶膜—电极/电容界面的封装参考。
- Salt‐Driven Silk Fibroin Assembly for Solvent‐Free Multienzyme Co‐Immobilization(Juan Cruz Almada, Miguel Marco‐Martín, Uriel A. Ruiz-Castillo, Susana Velasco-Lozano, 2026, ChemCatChem)
- Immobilization of laccases on mechanically ground silk fibroin nanofibers for enhanced stability.(Ayari Miyawaki, S. Sakai, 2024, International Journal of Biological Macromolecules)
- Silk‐Fibroin as Biocompatible and Bioresorbable Enzyme Immobilization Matrix for Screen‐Printed Amperometric Glucose Biosensors(K. Janus, Stefan Achtsnicht, B. Isella, A. Kopp, K. Miyamoto, T. Yoshinobu, M. Keusgen, M. Schöning, 2025, Advanced Sensor Research)
- Silk fibroin hydrogel encapsulated graphene filed-effect transistors as enzyme-based biosensors(Zhaoliang Wang, Hai-Yang Yu, Zheng Zhao, 2021, Microchemical Journal)
水凝胶载体行为调控与脂肪酶溶解/稳定性辅料
共同点:从载体理化性质与辅料配方角度保障酶活——水凝胶溶胀、力学与释放行为的可控调节,石墨烯-水凝胶杂化体系的对比研究(导电性、负载与稳定性),以及脂蛋白脂肪酶(LPL)关键赋形剂/稳定剂的筛选鉴定。直接支撑敏感膜在小体积皮下环境中的机械匹配、传质可控与酶(尤其脂肪酶)长期稳定性设计。
- Efficient Regulation of the Behaviors of Silk Fibroin Hydrogel via Enzyme-Catalyzed Coupling of Hyaluronic Acid.(Lin Wang, Feiyu Wang, Bo Xu, Man Zhou, Yuan-Yuan Yu, Ping Wang, Qiang Wang, 2020, Langmuir)
- A comparative study of graphene-hydrogel hybrid bionanocomposites for biosensing.(S. Burrs, D. Vanegas, Y. Rong, M. Bhargava, N. Mechulan, P. Hendershot, H. Yamaguchi, C. Gomes, E. Mclamore, 2015, In Analysis)
- Identification of key excipients for the solubilization and structural characterization of lipoprotein lipase, an enzyme for hydrolysis of triglyceride.(Weiqiang Cheng, Bing He, S. Basu, Pierre O. Souillac, 2021, Journal of Pharmacy and Science)
CardioMEMS无源植入监测的临床疗效与循证证据
共同点:以CardioMEMS肺动脉压力无源植入传感器为标杆,汇集随机对照试验与患者层面荟萃分析证明血流动力学指导管理显著降低心衰住院与全因死亡,并给出患者筛选、压力指导调药的标准化流程与临床获益机制。为『无源植入+长期连续监测可改变临床结局』提供最强循证背书,可类比迁移至犬猫胰腺炎、肾病等继发疾病的早期预警与干预。
- Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in "Real-World" Clinical Practice.(A. S. Desai, A. Bhimaraj, R. Bharmi, R. Jermyn, K. Bhatt, D. Shavelle, M. Redfield, R. Hull, J. Pelzel, K. Davis, Nirav Dalal, P. Adamson, J. Heywood, 2017, Journal of the American College of Cardiology)
- Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction.(J. Lindenfeld, M. Costanzo, M. Zile, A. Ducharme, R. Troughton, A. Maisel, M. Mehra, S. Paul, S. Sears, F. Smart, N. Johnson, J. Henderson, P. Adamson, A. Desai, W. Abraham, 2024, Journal of the American College of Cardiology)
- Management of the Patient with Heart Failure and an Implantable Pulmonary Artery Hemodynamic Sensor(J. Abraham, P. McCann, M. Guglin, A. Bhimaraj, Terrie-Ann S. Benjamin, M. Robinson, O. Jonsson, S. Feitell, K. Bhatt, Mosi K. Bennett, J. Heywood, 2020, Current Cardiovascular Risk Reports)
- Implantable devices for heart failure monitoring.(S. Ijaz, Sachin P. Shah, Arjun Majithia, 2021, Progress in cardiovascular diseases)
- CardioMEMS: dispositif implantable pour réduire les hospitalisations des insuffisants cardiaques(Joas Brandner, P. Meyer, S. Noble, N. Poku, 2025, Revue medicale suisse)
CardioMEMS在特殊人群与真实世界的拓展应用(儿科、LVAD、Fontan、PAH与运动负荷)
共同点:展示无源植入监测在儿科肺高压、LVAD管理、Fontan单心室循环、PAH右心衰等复杂/小尺寸人群中的植入可行性与临床获益,并在次极量运动负荷条件下量化血流动力学反应,体现『小尺寸、低负担器件+趋势预警』的跨人群适配边界。为犬猫(尤其小型犬猫)肩胛间皮下植入的尺寸约束、操作难度与跨物种迁移提供直接类比依据。
- Hemodynamic Monitoring of Pediatric Patients With Heart Failure and Pulmonary Hypertension Using CardioMEMS(C. Labrandero, L. Deiros, C. Abelleira, Viviana Arreo, E. Balbacid, F. Gutiérrez-Larraya, 2024, Journal of the Society for Cardiovascular Angiography & Interventions)
- Implanted Hemodynamic Monitoring in Management of Significant Right Heart Failure before and after Left Ventricular Assist Device Implantation: Creation and Maintenance of Fontan Physiology in Severe Right Ventricular Dysfunction(Kevin S. Yei, Casey Kaisi, R. Mohan, A. Srivastava, J. Heywood, 2018, The VAD Journal)
- The Utility of CardioMEMS Implantable Hemodynamic Monitoring Device in Heartware HVAD Patient with Recurrent Gastrointestinal Bleeding(H. Singh, V. Kittipibul, R. Flowers, S. Chaparro, 2019, The Journal of Heart and Lung Transplantation)
- Ambulatory Fontan pressure monitoring: Results from the implantable hemodynamic monitor Fontan feasibility cohort (IHM-FFC).(E. Bradley, Anudeep Jassal, M. Moore-Clingenpeel, W. Abraham, D. Berman, Curt J. Daniels, 2019, International Journal of Cardiology)
- Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor.(R. Benza, M. Doyle, D. Lasorda, K. Parikh, P. Correa-Jaque, N. Badie, G. Ginn, S. Airhart, V. Franco, M. Kanwar, S. Murali, A. Raina, Rahul Agarwal, S. Rajagopal, J. White, R. Biederman, 2019, Chest)
- Abstract 6202: Use of the CardioMEMS TM HF System to Guide Pulmonary Hypertensive Therapy in a Pediatric Patient with Restrictive Cardiomyopathy on Durable Mechanical Circulatory Support(N. Markiewitz, K. Lin, D. Frank, C. Ravishankar, Sarah Khan, M. O'Connor, A. Dewitt, B. Kozyak, J. Eichner, H. Ahmed, Jonathan J. Edwards, Anila A. Chaudhary, C. Wittlieb-Weber, J. Rossano, Katsuhide Maeda, C. Avitabile, J. Edelson, Mudit Gupta, 2026, Circulation)
- Ambulatory Hemodynamic Monitoring—Don’t Forget the Little Ones!(Varun Aggarwal, Athar M. Qureshi, 2024, Journal of the Society for Cardiovascular Angiography & Interventions)
- Applications of Implantable Hemodynamic Monitoring in the Setting of Durable Mechanical Circulatory Support.(F. Pagani, 2018, ASAIO journal (1992))
- Assessing Hemodynamic Response to Submaximal Exercise in Pulmonary Arterial Hypertension Patients Using an Implantable Hemodynamic Monitor(S. Airhart, N. Badie, M. Doyle, P. Correa-Jacque, Curt J. Daniels, R. Benza, 2021, The Journal of Heart and Lung Transplantation)
- Abstract 4353255: Estimating CardioMEMS Pulmonary Artery Diastolic Pressure With a Non-invasive Cardiac Hemodynamic Artificial Intelligence monitoring System (CHAIS)(Zachary Berger, R. Ringel, Samuel Roytburd, N. Ayalon, Deepa M. Gopal, L. Tsao, J. Guttag, C. Stultz, 2025, Circulation)
无源植入器械的安全性、并发症与失效模式
共同点:专门报告器械失效与安全性结局——传感器内皮化/纤维包裹导致波形衰减甚至需重新植入的个案,以及器械相关不良事件发生率的安全性画像。直接对应该芯片皮下植入后可能遇到的血管化与纤维包裹、信号衰减、放置部位选择与长期生物相容性风险,是可行性论证中不可或缺的风险清单。
- Dysfunctional Implantable Pulmonary Artery Sensor Device (CardioMEMS) in Group 2 Pulmonary Hypertension(A. Abdelkader, O. Ilonze, M. Guglin, 2025, JACC Case Reports)
- Abstract 4367586: Safety Profile of the CardioMEMS HF System in Pulmonary Arterial Hypertension: A Pooled Adverse Event Analysis from Three Clinical Studies(R. Benza, A. Rothman, Tatiane Abvreu Dall'Agnol, R. Agrawal, N. Daczkowski, B. Dahlof, Q. Duan, C. Gazzola, J. Guichard, Yan Liu, K. O'Connell, A. Waxman, R. White, R. Zolty, 2025, Circulation)
远程植入/可穿戴监测的技术谱系、发展趋势与临床转化路径
共同点:以综述与前景视角归纳远程血流动力学监测的技术谱系(肺动脉/左房/下腔静脉压力传感、CIED与可穿戴设备)与植入式生物电子/可穿戴生化传感的平台化趋势,并讨论获益落地障碍(数据整合、支付、流程标准化)。为项目在兽医场景的分层监测定位、从研究原型到临床/居家转化路径提供宏观框架。
- Current and Future Landscape of Remote Hemodynamic Monitoring.(Liviu Klein, 2025, Journal of Cardiac Failure)
- Implantable bioelectronics and wearable sensors for kidney health and disease(S. Madhvapathy, Soongwon Cho, E. Gessaroli, E. Forte, Yi-Rui Xiong, L. Gallon, J. Rogers, 2025, Nature Reviews Nephrology)
- The Utility of a Wireless Implantable Hemodynamic Monitoring System in Patients Requiring Mechanical Circulatory Support(D. Feldman, N. Moazami, P. Adamson, J. Vierecke, N. Raval, S. Shreenivas, B. Cabuay, Javier Jiménez, W. Abraham, J. O'Connell, Y. Naka, 2017, ASAIO journal (1992))
犬猫高脂血症(高甘油三酯)流行病学、胰腺炎风险与临床监测缺口
共同点:确立项目临床痛点与适应人群——犬猫高甘油三酯血症/高胆固醇血症与体况指数(肥胖)的关联流行病学、高甘油三酯作为急性胰腺炎独立危险因素的风险证据、犬胰腺炎诊疗规范,以及餐后血清甘油三酯动态波动对单次抽血判读的影响。共同论证『老年犬猫早期无症状、院内抽血无法连续监测』的筛查缺口与长期连续血脂预警的必要性。
- Hypertriglyceridemia as a risk factor for complications of acute pancreatitis and the development of a severity prediction model.(K. Song, Zuo-Yan Wu, J. Meng, Wei Tian, Shicheng Zheng, Dong Mu, Ruifeng Wang, H. Pang, Dong Wu, 2023, HPB)
- Hypertriglyceridemia, Hypercholesterolemia, Body Mass Index, and the Risk of Acute Pancreatitis(Qiu-Hong Sun, Li-Ming Du, Qing-Shuai Ren, Guo-Ling Zhu, Bing Zhang, Afang Su, Shou-Ling Wu, S. Chen, 2024, Digestive Diseases and Sciences)
- CANINE PANCREATITIS : DIAGNOSIS AND MANAGEMENT(P. J. Armstrong, 2011, No journal)
- Association of postprandial serum triglyceride concentration and serum canine pancreatic lipase immunoreactivity in overweight and obese dogs.(K. Verkest, L. Fleeman, J. Morton, S. J. Groen, J. Suchodolski, J. Steiner, J. Rand, 2012, Journal of Veterinary Internal Medicine)
将多组初始化分组按『物理原理—结构增敏—体内实现—生化识别—材料基质—临床背书—临床依据』重新归并为15个互不交叉的一级分组:(1) 无源LC谐振传感与射频耦合读取原理(含耦合建模、阻抗/谐振匹配、频移解调、鲁棒性及综述指出的封装—漂移局限);(2) LC微系统集成与电容式敏感结构(MEMS/CMOS、叉指电容、RFID温度、宽禁带无电池传感);(3) 高灵敏柔性LC压力/多参数敏感结构与增敏设计(双螺旋、眼压、温压双参数、球面电容);(4) 皮下/间质液无源无线传感的植入式可行性与在体验证(含无源LC I-tag原型与射频供电葡萄糖传感);(5) 组织液—血液相关性与分子监测模型验证(甲氨蝶呤、乳酸、乙醇、近红外多孔硅等);(6) 微针/导管式微创取液与长期植入器件工程(自校准阵列、抗污损、寿命管理);(7) 三联酶级联甘油三酯传感体系与共固定化工艺;(8) 多酶级联定向组装与纳米/电极界面增效;(9) 丝素蛋白水凝胶酶固定基质与多酶共固定微环境;(10) 水凝胶载体行为调控与脂肪酶稳定辅料;(11) CardioMEMS临床疗效与循证证据;(12) CardioMEMS在儿科/LVAD/Fontan/PAH等特殊人群与真实世界的拓展;(13) 无源植入器械安全性、并发症与失效模式(单列以突出风险清单);(14) 远程植入/可穿戴监测技术谱系与转化路径;(15) 犬猫高脂血症流行病学、胰腺炎风险与临床监测缺口。合并中去除了原有的三级重叠(如无源LC组同时出现在三条主线、catheter电极文章重复列于多组),每个bibkey仅归属一个分组,共覆盖76篇文献。尚存的知识缺口:兽医专用的皮下ISF甘油三酯—血脂对照研究、犬猫在体酶传感器/植入器械案例、以及伴侣动物器械注册与居家监测依从性证据较少,建议后续补充兽医临床检验与宠物医疗器械转化类文献以强化痛点与落地论证。
共同点:围绕无源LC谐振器在射频电感耦合链路上的物理与电路问题展开——谐振网络参数优化与耦合感知自适应、中继/负载阻抗匹配以最大化感应电流、基于谐振频率的动态前端监测、自动谐振调谐与频率可调LC结构、集成无源元件与读取电路设计、以及谐振频率扰动下的鲁棒性提升;并含一篇系统综述,指出封装、耦合距离、温漂与老化漂移等共性局限。构成芯片『无电池、隔空供电+频移读出』的链路层基础,并给出长期标定与稳定性风险清单。相关文献:Yunfang Zhang et. al, 2026 等 9 篇文献
共同点:从器件集成与敏感电容结构层面研究无源LC传感的实现方式——硅基/CMOS工艺的无源LC微系统、电感-电容谐振回路的MEMS电容式无线敏感、叉指电容作为增敏换能单元的结构参数—灵敏度规律、RFID型温度传感、以及可在高温/恶劣环境工作的宽禁带SiC无电池无线传感器,并提供典型LC结构的设计与特性表征范例。为芯片的敏感电容(酶膜介电/电容变化)设计与微纳制造工艺路线提供可移植方案。相关文献:Pichao Pan et. al, 2025 等 6 篇文献
共同点:以压力、眼压、温度等物理量为模型,量化无源LC谐振器在灵敏度、耦合距离、检测限上的设计权衡——超高灵敏柔性LC压力传感、双螺旋谐振接触式传感、微加工眼压传感、双参数(压力+温度)无源传感及球面电容式谐振传感器。其灵敏度—尺寸—封装折中方法与双敏感/差分抗干扰思路,可直接迁移到『酶膜响应→谐振频移』的甘油三酯敏感结构设计。相关文献:Hai-Rong Kou et. al, 2025 等 6 篇文献
共同点:把无源LC/射频耦合原理真正落地到皮下场景——可穿透多层皮肤无线读取的电池free体腔内传感器、皮下穿孔胶囊连续监测组织液压力、绷带下柔性LC谐振器在犬类创面模型中的在体验证、射频供电的植入式葡萄糖生物传感器,以及以二极管调制无源LC标签实现深层组织标志物监测的电磁传感平台。共同证明『微创植入+隔空供能与读取+体液/生理量长期连续监测』在真实动物与人体中的工程可行性,是本项目芯片架构最接近的技术原型。相关文献:Mingke Yang et. al, 2025 等 5 篇文献
共同点:以具体分子为模型,论证皮下组织液浓度可替代/反映血浆浓度的前提条件与局限——ISF-血浆对应关系与组织液屏障、乳酸在ISF中的连续监测可行性、乙醇蒸气在体无线检测、免标记近红外多孔硅植入式生物传感,以及薄膜硝化纤维电致分解的原位取样/信号转换方法。为『皮下组织液甘油三酯可反映血脂水平』提供方法学依据,同时提示时间滞后、蛋白吸附与个体差异风险。相关文献:J. M. Gibson et. al, 2026 等 5 篇文献
共同点:面向长期植入的器件工程问题——自校准多路复用微针电极阵列、微针电化学生物传感器进展综述、导管式电极实现连续适配体检测、可贴附兼可植入的聚合物微针、开窗式微针乳酸连续监测、中空微针PB基传感。共同解决酶降解、生物污损、信号漂移与器件寿命问题,其尺寸约束、抗污损涂层与自校准策略可直接指导本项目敏感膜寿命管理与校准流程。相关文献:Xiang-Ling Li et. al, 2025 等 6 篇文献
共同点:以脂肪酶(脂蛋白脂肪酶)→甘油激酶→甘油-3-磷酸氧化酶(±过氧化物酶)级联为识别核心,研究甘油三酯的酶解、共固定化方式(如戊二醛交联于PVC条)、最适pH/温度与可重用性,以及电流型/生物电催化型传感器在血清样本中的线性范围、检出限与抗干扰性能。为本项目敏感膜的酶体系组成、固定化工艺与定量标定提供最直接依据。相关文献:N. Chauhan et. al, 2014 等 5 篇文献
共同点:聚焦提升级联效率与信号转换增益的通用策略——多酶级联的空间定位组装以缩短中间产物扩散距离、纳米颗粒平台的理性设计以放大催化/电学响应、叉指电极酶传感器构型优化。为将三联酶级联产物(H2O2/酸化/介电变化)高效转换为可被LC前端量化的电学或介电偏移提供技术选项。相关文献:Shiyi Che et. al, 2020 等 3 篇文献
共同点:以丝素蛋白为核心材料,通过盐驱动自组装/机械研磨纳米纤维等无溶剂或温和工艺实现多酶在同一蛋白基质中的共包埋与级联化学计量比调控,并显著提升操作稳定性、热稳定性与储存寿命;同时包括丝素水凝胶与石墨烯/场效应器件的封装集成案例。构成敏感膜『生物相容、可降解、可长期保持酶活』的材料学依据,并给出酶膜—电极/电容界面的封装参考。相关文献:Juan Cruz Almada et. al, 2026 等 4 篇文献
共同点:从载体理化性质与辅料配方角度保障酶活——水凝胶溶胀、力学与释放行为的可控调节,石墨烯-水凝胶杂化体系的对比研究(导电性、负载与稳定性),以及脂蛋白脂肪酶(LPL)关键赋形剂/稳定剂的筛选鉴定。直接支撑敏感膜在小体积皮下环境中的机械匹配、传质可控与酶(尤其脂肪酶)长期稳定性设计。相关文献:Lin Wang et. al, 2020 等 3 篇文献
共同点:以CardioMEMS肺动脉压力无源植入传感器为标杆,汇集随机对照试验与患者层面荟萃分析证明血流动力学指导管理显著降低心衰住院与全因死亡,并给出患者筛选、压力指导调药的标准化流程与临床获益机制。为『无源植入+长期连续监测可改变临床结局』提供最强循证背书,可类比迁移至犬猫胰腺炎、肾病等继发疾病的早期预警与干预。相关文献:A. S. Desai et. al, 2017 等 5 篇文献
共同点:展示无源植入监测在儿科肺高压、LVAD管理、Fontan单心室循环、PAH右心衰等复杂/小尺寸人群中的植入可行性与临床获益,并在次极量运动负荷条件下量化血流动力学反应,体现『小尺寸、低负担器件+趋势预警』的跨人群适配边界。为犬猫(尤其小型犬猫)肩胛间皮下植入的尺寸约束、操作难度与跨物种迁移提供直接类比依据。相关文献:C. Labrandero et. al, 2024 等 10 篇文献
共同点:专门报告器械失效与安全性结局——传感器内皮化/纤维包裹导致波形衰减甚至需重新植入的个案,以及器械相关不良事件发生率的安全性画像。直接对应该芯片皮下植入后可能遇到的血管化与纤维包裹、信号衰减、放置部位选择与长期生物相容性风险,是可行性论证中不可或缺的风险清单。相关文献:A. Abdelkader et. al, 2025 等 2 篇文献
共同点:以综述与前景视角归纳远程血流动力学监测的技术谱系(肺动脉/左房/下腔静脉压力传感、CIED与可穿戴设备)与植入式生物电子/可穿戴生化传感的平台化趋势,并讨论获益落地障碍(数据整合、支付、流程标准化)。为项目在兽医场景的分层监测定位、从研究原型到临床/居家转化路径提供宏观框架。相关文献:Liviu Klein et. al, 2025 等 3 篇文献
共同点:确立项目临床痛点与适应人群——犬猫高甘油三酯血症/高胆固醇血症与体况指数(肥胖)的关联流行病学、高甘油三酯作为急性胰腺炎独立危险因素的风险证据、犬胰腺炎诊疗规范,以及餐后血清甘油三酯动态波动对单次抽血判读的影响。共同论证『老年犬猫早期无症状、院内抽血无法连续监测』的筛查缺口与长期连续血脂预警的必要性。相关文献:K. Song et. al, 2023 等 4 篇文献
总计 76 篇相关文献
No abstract available
No abstract available
This paper details a passive, inductor-capacitor (LC) resonant sensor embedded in a commercial dressing for low-cost, contact-free monitoring of a wound; this would enable tracking of the healing process while keeping the site closed and sterile. Spiral LC resonators were fabricated from flexible, copper-coated polyimide and interrogated using external reader antennas connected to a two-port vector network analyzer; the forward transmission scattering parameter (S21) magnitude was collected, and the resonant frequency (MHz) and the peak-to-peak amplitude of the resonant feature were identified. These increase during the healing process as the permittivity and conductivity of the tissue change. The sensor was first tested on gelatin-based tissue-mimicking phantoms that simulate layers of muscle, blood, fat, and skin at varying phases of wound healing. Finite element modeling was also used to verify the empirical results based on the expected variations in dielectric properties of the tissue. The performance of the resonant sensors for in vivo applications was investigated by conducting animal studies using canine patients that presented with a natural wound as well as a controlled cohort of rat models with surgically administered wounds. Finally, transfer functions are presented that relate the resonant frequency to wound size using an exponential model (R2 = 0.58-0.96). The next steps in sensor design and fabrication as well as the reading platform to achieve the goal of a universal calibration curve are then discussed.
Herein, a passive low-profile moisture sensor design based on radio frequency identification (RFID) technology is proposed. The sensor consists of an LC resonant loop, and the sensing mechanism is based on the fringing electric field generated by the capacitor in the circuit. A standard planar inductor and a two-layer interdigital capacitor (IDC) with a significantly higher fringing capacitance compared to that of a conventional parallel plate capacitor (PPC) are used, resulting in improved frequency offset and sensitivity of the sensor. Furthermore, a sensor tag was designed to operate at an 8.2 MHz electronic article surveillance (EAS) frequency range and the corresponding simulation results were experimentally verified. The IDC- and PPC-based capacitor designs were comprehensively compared. The proposed IDC sensor exhibits enhanced sensitivity of 10% in terms of frequency offset that is maintained over time, increased detection distance of 5%, and more than 20% increase in the quality factor compared to sensors based on PPC. The sensor’s performance as a urine detector was experimentally qualified. Additionally, it was shown experimentally that the proposed sensor shows a faster response to moisture. Both simulation and experimental data are presented and elucidated herein.
Measurement technology for various key parameters in harsh environments (e.g., high-temperature and biomedical applications) continues to be limited. Wireless passive LC resonant sensors offer long service life and can be suitable for harsh environments because they can transmit signals without battery power or wired connections. Consequently, these devices have become the focus of many current research studies. This paper addresses recent research, key technologies, and practical applications relative to passive LC sensors used to monitor temperature, pressure, humidity, and harmful gases in harsh environments. The advantages and disadvantages of various sensor types are discussed, and prospects and challenges for future development of these sensors are presented.
This paper presents a wireless passive inductor-capacitor (LC) temperature sensor with controllable structural parameters and adjustable frequency. Combining an equivalent circuit model with electromagnetic simulation, the regulation laws of coil turns and dielectric layer thickness on the resonant frequency are quantitatively analyzed. Since the fundamental mechanism of LC frequency tuning is well-understood, the core contribution of this work lies in the specific characterization of the proposed sensor architecture, verifying the feasibility of achieving frequency-on-demand design through geometric optimization. In terms of manufacturing, Zinc (Zn) foil is used as the inductor material, and thermosensitive Polyethylene Glycol (PEG) is utilized as the dielectric layer. The sensor prototype is fabricated using laser micro-machining and lamination processes. Experimental results demonstrate that the sensor exhibits good linearity within the physiological temperature range, with an average sensitivity of 0.6 MHz/°C. Furthermore, it maintains effective wireless signal transmission at a coupling distance of up to 18 mm. This study provides theoretical basis and technical support for the frequency customization and structural design of wireless passive sensors.
No abstract available
In this work we present a development of a reusable wireless non-enzyme glucose sensor based on the resonant inductor-capacitor (LC) passive circuit fabricated explicitly on a low-cost FR4 substrate. In our experiments, glucose/water solutions with varying concentrations have been utilized to evaluate the characteristics of the proposed structure. The obtained results showed that the fabricated sensor’s effectiveness in accurately identifying glucose concentrations ranging from 0.1 mM to 100 mM. The sensor’s sensitivities were estimated to be 9.595 MHz/mM, 0.7659 MHz/mM, and 0.2709 MHz/mM for 0.1 to 0.9 mM, 1 to 10 mM, and 10 to 100 mM glucose concentration ranges, respectively. The sensor’s limit of detection (LOD) was calculated to be 0.105 mM for the glucose range from 0.1 to 0.9 mM. In particular, the sensitivity changes most significantly within the glucose concentration range of 0.1 to 0.9 mM, indicating that the sensor is particularly effective at detecting lower glucose concentrations. The obtained characteristics suggest that this sensor is suitable for applications requiring precise measurements of glucose solution.
No abstract available
In this paper, we report an LC microsystem with the potential for passive wireless measurement of pulmonary artery (PA) pressure, which consists of a micromachined pressure-sensitive capacitor based on a low-resistance silicon substrate (CLRS) or intrinsic silicon substrate (CIS) and a PCB-based planar spiral inductor in parallel. The integrated capacitor, fabricated using MEMS technology, has dimensions of 11*2.6*0.5mm, much smaller than the size of the PA. Despite its compact size, the capacitor has a capacitance of up to about 12pF due to the 1.5μm short cavity gap, while the pull-in effect is effectively avoided during the anodic bonding process by introducing an optimized electrostatic shielding design with local equipotential leads. The resonant frequency of the LC microsystem shifts from 27.38MHz to 26.57MHz at various external pressures of 0-100mmHg, with a sensitivity up to 8.1kHz/mmHg, a nonlinearity of 0.43%, and a Q-factor of more than 10. These results demonstrate the capability of the proposed system for continuous PA pressure monitoring.
This study presents a highly sensitive wireless passive flexible pressure sensor. The sensor employs an ionic film as the dielectric layer, utilizes a spiral coil as the antenna for transmitting and receiving signals of the sensor, and adopts a sandwich process to complete the fabrication of the sensor. This study validates through circuit analysis and simulation that the sensor can be used for wireless passive detection of pressure information. First, the performance of the ionic film is examined. The sensor fabricated with the ionic film has high sensitivity (38.74 N-1), fast response time (100 ms), and high stability. This study also tests the wireless transmission performance between the sensor and the antenna. The test results indicate that the sensor can achieve wireless signal detection within a range of 13 mm. The pressure sensitivity of the sensor in the range of 0–0.5 N is 394.94 MHz/N. When the applied pressure increases from 0.5 to 10 N, the resonant frequency of the sensor decreases from 210 to 160 MHz, and the pressure sensitivity is 4.15 MHz/N. The sensor can realize palm bending detection, breathing, and voice recognition, and has extensive application prospects in the fields of human-computer interaction and wearables.
Aiming at the problem that the sensitivity of LC pressure sensors is restricted due to the use of single inductance or single capacitance sensing mechanisms, the paper proposes a highly sensitive flexible LC pressure sensor based on a dual-sensing mechanism. The anisotropically distributed nano-iron particles doped porous polydimethylsiloxane (PDMS) film and ferrite film are respectively used as the capacitance and inductance sensitive layers of the pressure sensor. The capacitance is affected by the change in dielectric constant of the porous PDMS film under different compression states. The change in distance between the LC resonant circuit and the ferrite film will cause a change in the effective magnetic permeability, hence achieving a controllable response of the inductance in the LC circuit. Based on the dual sensitive mechanism of the cooperative response of inductance and capacitance under pressure, the resonant frequency of the LC sensor can be significantly shifted, thereby breaking through the limitation of improving the sensitivity of the LC pressure sensor. In addition, ferrite films can effectively shield metal signal interference, consequently enhancing the stability and accuracy of wireless detection signal transmission performance. Within the pressure range of 0–10 kPa, the sensitivity of the sensor is 434.64 kHz kPa−1, the signal quality factor is 30, and the maximum hysteresis error and maximum repeatability deviation are less than 0.723% and 0.4 MHz respectively. Through the dual sensitivity mechanism of inductance and capacitance, the sensor achieves highly sensitive pressure detection. Its flexible structure and high sensitivity are particularly suitable for applications such as wearable health monitoring and human–computer interaction, and provide new ideas for the optimized design of flexible LC pressure sensors.
This paper presents a wireless passive spherical capacitive-based resonant sensor for in-situ underground soil moisture monitoring. The sensor features a hollow spherical structure housing a resonant coil and orthogonally arranged capacitive sensing electrodes, forming an LC tank circuit with its resonant frequency shifting in response to soil moisture change. An outer spherical encapsulation provides a lcm clearance around the sensing elements, thus ensuring a high-Q resonance, critical for the wireless operation through soil. The system employs a two-phase inductively coupled operation: in Phase-I, an RF energy is wirelessly transferred to the sensor from above-ground; in Phase-2, the sensor's exponentially decaying response exhibiting a moisture dependent frequency is detected. Laboratory characterization demonstrates a sensitivity of 30fF per 1 % of volumetric moisture change and reliable communication through 15 cm of soil.
This paper presents an electromagnetic sensor platform for monitoring deep-tissue biomarkers, utilizing tuning circuit principles. The implant-target (I-tag) includes a biomarker sensing frontend, diodes, and a spiral coil-based inductor-capacitor resonant coil. Compared to solutions with integrated active chips, the I-tag improves size, safety, and power consumption. The sensing frontend converts electrochemical signals into voltage signals applied across the diodes. In the resonant circuit, coupling between the patch system's coil and the implanted coil, aided by the diodes, translates potential changes into resistance modulation, resulting in a quantifiable offset. Unlike traditional interrogation techniques using vector network analyzers, this paper introduces a simple patch system employing a coherent demodulation technique, implemented with printed circuit board technology and commercially available components. The platform's performance was validated through experiments, achieving an RMSE of 0.1764 and a detectable distance of up to 12 mm.
Introduction CardioMEMS heart sensor is a wireless implantable hemodynamic monitoring system that can guide the management of heart failure (HF). Its role in HF patients with left-ventricular assist device (LVAD) is undetermined. Gastrointestinal (GI) bleeding is a common complication in the LVAD population. Severe GI bleeding can lead to a hypovolemic state which results in decreased pulmonary artery pressure (PAP). In this case, we report the changes in PAP recorded by CardioMEMS in an LVAD patient with recurrent GI bleeding. Case Report A 66 year-old man with Heartware HVAD implantation for ischemic cardiomyopathy, atrial fibrillation, diabetes and CardioMEMS device implantation presented to the emergency department (ED) on 6/8 due to black stools for 4 days. He was hospitalized 3 times in the preceding 2 months for GI bleeding of unclear etiology requiring blood transfusions and monthly octreotide. In the ED, he was stable and LVAD interrogation did not show any events. However, he had a drop in hemoglobin (Hb) from a baseline of 8.9 g/dL to 6.9 g/dL. He underwent push enteroscopy during this hospital stay which demonstrated bleeding jejunal angioplastic lesions. The PAP readings during the episodes of GI bleeding were reviewed. There was a significant reduction in PAP at the date of symptom onset from one day prior; from 57/26 mmHg (mPAP 38 mmHg) on 6/3 to 48/24 mmHg (mPAP 34 mmHg) on 6/4 corresponding with 2 g/dL drop in Hb level (See figure). This phenomenon was seen in a prior episode of GI bleeding 2 months prior. The PAP numbers dropped considerably to 39/18 mmHg (mPAP 27 mmHg) at the onset of symptoms compared with 49/22 mmHg (mPAP 33 mmHg) 1 day prior associated with 2.9 g/dL decline in Hb level. During the time PAP changes were observed, diuretic therapy was not modified. Summary In patients implanted with CardioMEMS device, a sudden drop in PAP can herald a GI bleeding episode. Monitoring PAP trends can be helpful in LVAD patients who are at higher risk for GI bleeding.
Introduction: The implantable CardioMEMS Heart Failure (HF) system, which monitors pulmonary arterial pressures in an outpatient setting, has been shown to reduce HF hospitalizations and improve functional status in patients with chronic heart failure. However, implantation is invasive and entails risk. Recent evidence suggests that a Cardiac Hemodynamic Artificial Intelligence System (CHAIS) can non-invasively identify when the mean pulmonary capillary wedge pressure (mPCWP) is elevated using ECG Lead-I signals. In this pilot study, we test whether CHAIS, without any retraining, can identify when the pulmonary artery diastolic pressure (PADP) – a correlate of the mPCWP – is elevated using ECG Lead-I signals obtained from a wearable ECG monitor. Hypothesis: CHAIS can determine when CardioMEMS-derived PADP is elevated. Methods: Ten adults (1 female, age 72 ± 11 years) with chronic HF and CardioMEMS implants were enrolled at Boston Medical Center (BMC, n=6, IRB H-44263) and Massachusetts General Hospital (MGH, n=4, IRB 2023P001291). Participants wore a single-lead ECG patch for up to 14 days. ECG data was segmented into 10 second windows, pre-processed, and input to CHAIS, which returned the probability of mPCWP > 18 mmHg. CHAIS probabilities were matched to CardioMEMS-derived PADP, producing N=76 contemporaneous pairs across all 10 patients. Results: CHAIS showed strong discriminatory ability for identifying when CardioMEMS PADP > 18 mmHg, yielding an overall AUC of 0.82 (BMC 0.85; MGH 0.81). After excluding eight ECG signals with poor signal quality (resulting in N=68 ECG-PADP pairs), the overall AUC rose to 0.85 (BMC 0.86; MGH 0.93). Moreover, CHAIS output was positively associated with contemporaneous CardioMEMS PADP (Pearson r=0.36, Spearman ρ=0.45 with N=76 and Pearson r=0.42, ρ=0.51 with N=68; all p < 0.001). P-values were computed via permutation testing using 25,000 resamples. Conclusion: This is the first study to demonstrate that a deep-learning model (CHAIS) can discriminate for elevated PADP using ECG signals obtained from a wearable ECG monitor. This non-invasive low-cost methodology for hemodynamic monitoring could expand HF surveillance, especially for patients who are ineligible to receive an invasive device. Fine-tuning CHAIS on wearable ECG data would improve its ability to non-invasively identify patients at risk for a HF exacerbation.
Background The CardioMEMS is an implantable device for hemodynamic monitoring approved by the US Food and Drug Administration for adult patients with heart failure. It has been used in the adult population without structural heart disease and with congenital heart diseases, but we do not have data in the pediatric population. Methods We report the initial single-center experience of the CardioMEMS implantation in children. Feasibility of device implantation, procedural outcomes, and clinical utility in the pediatric population were evaluated. Results The CardioMEMS device was implanted without technical complications in 8 pediatric patients (mean age 7 years and mean weight 27.9 kg) with pulmonary hypertension (6/8, 75%) and heart failure (2/8, 25%). The device was delivered via femoral access in 7 (85%) patients and implanted in the left pulmonary artery in 7 (85%). The noninvasive recording of pulmonary pressures in patients with pulmonary hypertension allowed the monitoring of the evolution of mean pulmonary artery pressure, intensifying vasodilator treatment, and avoiding control cardiac catheterizations. In patients with heart failure, pulmonary hemodynamic monitoring guided the decongestive treatment prior to heart transplantation. Conclusions The implantation of CardioMEMS in the pediatric population is a feasible procedure that allows the noninvasive hemodynamic monitoring of patients with heart failure and pulmonary hypertension. Its implementation in selected patients aids in outpatient follow-up and therapeutic management of patients with complex cardiac conditions, avoiding invasive procedures that require hospitalization. Further large-scale studies in the pediatric population are recommended.
BACKGROUND Trials evaluating implantable hemodynamic monitors to manage patients with heart failure (HF) have shown reductions in HF hospitalizations but not mortality. Prior meta-analyses assessing mortality have been limited in construct because of an absence of patient-level data, short-term follow-up duration, and evaluation across the combined spectrum of ejection fractions. OBJECTIVES The purpose of this meta-analysis was to determine whether management with implantable hemodynamic monitors reduces mortality in patients with heart failure and reduced ejection fraction (HFrEF) and to confirm the effect of hemodynamic-monitoring guided management on HF hospitalization reduction reported in previous studies. METHODS The patient-level pooled meta-analysis used 3 randomized studies (GUIDE-HF [Hemodynamic-Guided Management of Heart Failure], CHAMPION [CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients], and LAPTOP-HF [Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy]) of implantable hemodynamic monitors (2 measuring pulmonary artery pressures and 1 measuring left atrial pressure) to assess the effect on all-cause mortality and HF hospitalizations. RESULTS A total of 1,350 patients with HFrEF were included. Hemodynamic-monitoring guided management significantly reduced overall mortality with an HR of 0.75 (95% CI: 0.57-0.99); P = 0.043. HF hospitalizations were significantly reduced with an HR of 0.64 (95% CI: 0.55-0.76); P < 0.0001. CONCLUSIONS Management of patients with HFrEF using an implantable hemodynamic monitor significantly reduces both mortality and HF hospitalizations. The reduction in HF hospitalizations is seen early in the first year of monitoring and mortality benefits occur after the first year.
No abstract available
No abstract available
Heart failure remains a leading cause of morbidity, mortality, and health care costs in the United States. Traditional management based on intermittent clinic visits and subjective symptom reporting often fails to detect early decompensation. Remote monitoring technologies-both invasive and noninvasive-are emerging as transformative tools for continuous, real-world surveillance of physiological parameters to guide heart failure management. This review provides a comprehensive overview of the current and evolving landscape of remote hemodynamic monitoring, including left atrial, pulmonary artery, and inferior vena cava pressure sensors, as well as cardiovascular implantable electronic devices and wearable systems. Devices such as the CardioMEMS and Cordella have demonstrated decreases in heart failure hospitalizations and improvements in quality of life through hemodynamic-guided therapy. Noninvasive technologies, including patch-based sensors, wearable monitors, and artificial intelligence-driven voice analysis platforms, show promise for broader scalability. Despite demonstrated benefits, adoption remains limited owing to data integration challenges, reimbursement barriers, and a lack of standardized clinical workflows. To fully realize the potential of remote monitoring, strategies must focus on patient engagement, closed-loop feedback systems, integration with electronic health records, and personalized algorithms. A tiered approach that matches monitoring intensity to disease severity may optimize outcomes and transform heart failure care into a proactive, patient-centered model.
BACKGROUND Pulmonary arterial hypertension (PAH) is a chronic disease that ultimately progresses to right-sided heart failure (HF) and death. Close monitoring of pulmonary artery pressure (PAP) and right ventricular (RV) function allows clinicians to appropriately guide therapy. However, the burden of commonly used methods to assess RV hemodynamics, such as right heart catheterization, precludes frequent monitoring. The CardioMEMS™ HF System is an ambulatory implantable hemodynamic monitor, previously only used in NYHA Class III HF patients. In this study, we evaluate the feasibility and early safety of monitoring PAH patients with right-sided heart failure (HF) using the CardioMEMS system. METHODS CardioMEMS sensors were implanted in 26 PAH patients with NYHA class III or IV right-sided HF (51.3±18.3 years old, 92% female, 81% NYHA class III). PAH therapy was tracked using a minimum of weekly reviews of CardioMEMS daily hemodynamic measurements. Safety, functional response, and hemodynamic response were tracked up to 4 years with in-clinic follow-ups. RESULTS CardioMEMS was safely used to monitor PAH therapy, with no device-related serious adverse events observed and a single pre-implant serious adverse event. Significant PAP reduction and cardiac output (CO) elevation were observed as early as 1 month post-implant using trends of CardioMEMS data, coupled with significant NYHA class and quality of life improvements within 1 year. CONCLUSIONS The CardioMEMS HF System provided useful information to monitor PAH therapy, and demonstrated short- and long-term safety. Larger clinical trials are needed before its widespread use to guide therapy in severe PAH patients with right-sided HF.
Implantable hemodynamic devices like the CardioMEMS HF System are commonly used to manage fluid status in patients with heart failure (HF) by measuring pulmonary pressures. Although CardioMEMS has been shown to reduce HF hospitalizations, rare complications (eg, device endothelialization) can occur and warrant clinical attention. A 67-year-old woman with HF with preserved ejection fraction and group 2 pulmonary hypertension experienced recurrent HF exacerbations. Despite optimal therapy, she was not a candidate for advanced HF therapies. The CardioMEMS device, initially effective for fluid management, showed dampened waveforms due to endothelialization, leading to reimplantation. Endothelialization is a rare but significant complication that can dampen pressure waveforms. Proper placement in vessels larger than 7 mm and careful monitoring of waveforms can help manage this issue. Device recalibration can usually address most cases; however, reimplantation may be required.
Heart failure affects 2 % of adults and remains a major challenge due to its high morbidity and mortality. Despite optimal treatment, repeated hospitalizations are a burden for patients and healthcare systems. Silently increasing filling pressures lead to pulmonary congestion and cardiac decompensation. Detecting these elevations before symptoms occur is critical. The CardioMEMS validated system, implanted in the pulmonary artery, now provides real-time hemodynamic monitoring. Linked to telemedicine, it allows early optimization of diuretics in order to prevent decompensation and hospitalization, thereby improving the management of heart failure.
The management of pediatric patients with heart failure and pulmonary hypertension remains a signi fi cant challenge, often requiring frequent hospitalizations and invasive procedures, including cardiac catheterization to monitor disease progression and guide treatment. Monitoring hemodynamic parameters in children with these conditions is critical for optimizing treatment and improving outcomes. The CardioMEMS HF System (Abbott) is an FDA-approved implantable sensor that wirelessly transmits pulmonary artery pressure data, allowing for noninvasive, ambulatory monitoring of hemodynamics. 1 – 3 The CardioMEMS device has revolutionized the management of heart failure in adults by providing pulmonary artery pressure monitoring, enabling timely intervention, and reducing hospital readmissions. Although the device has been extensively studied and utilized in the adult heart failure population, data on its application in the pediatric setting have been lacking.
BACKGROUND Implantable invasive hemodynamic monitoring (IHM) using the CardioMEMS™ HF system has been shown to reduce heart failure (HF) hospitalizations. IHMs have not yet been used in congenital heart disease (CHD). We aimed to evaluate feasibility and mid-term outcomes of IHM use in the single ventricle/Fontan population. METHODS Six adult Fontan patients (>1 HF admission, NYHA FC >3) were enrolled (30 ± 7 years old, mean pulmonary artery pressure (mPA) 16 ± 4.7 mm Hg). Heart failure mediated events (HFME) were evaluated for 12 months: CV medication change, hospital admission, paracentesis, and change in orthotopic heart transplant (OHT) listing status. RESULTS The IHM device was successfully placed in all participants. In total there were 671 IHM transmissions and 25(3.7%) HFME. The mean PA pressure across all episodes was 18.2 ± 6.6 mm Hg (range 6-40 mm Hg). Higher mPA pressures were associated with greater odds of having a HFME (OR 1.17 [1.09, 1.25], p < 0.0001). Mean PA pressure had good ability to discriminate transmissions associated with HFME (AUC 0.76 [0.654, 0.866]), with mean PA pressures >24 mm Hg or individual mPA change >4 mm Hg, best discriminating transmissions associated with HFME. CONCLUSIONS In the first feasibility series of adult Fontan patients undergoing CardioMEMS™ implantation we demonstrate early technical success and no device-related adverse events. We propose that ambulatory mean PA pressures >24 mm Hg or individual mPA change >4 mm Hg may be associated with more HFME. Further large-scale studies in this population are recommended.
Pulmonary arterial hypertension (PAH) is a chronic, progressive disease that is incurable, even with effective therapy. Long-term outcome in PAH is best preserved by targeting hemodynamic improvements to reduce risk of subsequent right ventricular (RV) failure. Methods that can assess RV adaptation to stress have important implications to better understand an individual’s physiology and may play a pivotal role in guiding therapy in PAH. In this novel pilot study, we evaluate the feasibility of monitoring hemodynamic response to 6 minute walk distance (6MWD) in patients with PAH using the CardioMEMS HF System.
No abstract available
Introduction: Pulmonary arterial hypertension (PAH) is a progressive disease. Continuous hemodynamic monitoring may help manage more severe PAH. The CardioMEMS HF System, an implantable pulmonary artery pressure (PAP) monitoring device, has shown promise in PAH management. However, its safety in patients with PAH remains undefined. Hypothesis: The use of the CardioMEMS is associated with an acceptable safety profile in patients with PAH. Methods: Adverse event data were combined from the completed CS1-003 (NCT05224531), on-going ARTISAN (NCT05203510), and on-going FIT_PH (NCT04078243) studies. Baseline assessments included demographics, hemodynamics, N-terminal pro B-type natriuretic peptide (NT-proBNP), 6-minute walk test (6MWT), and WHO Functional Class. Safety data were collected throughout each study. Results: At the time of analysis, 129 patients had received a CardioMEMS implant across the CS1-003 (n=25), ARTISAN (n=49), and FIT_PH (n=55) studies. All patients were diagnosed with PAH, with idiopathic, heritable, or drug/toxin-induced etiologies accounting for 81.4% of the cases, and connective tissue disease for 14.7%. The mean age was 54.6 years (range: 19-84), with 73.6% female patients. Most patients (77.5%) were classified as WHO Functional Class III or IV. The pooled means of baseline hemodynamic parameters were as follows: mean PAP of 47.9 mmHg (range: 23–81), mean right atrial pressure of 8.2 mmHg (range: 1–25), pulmonary artery wedge pressure of 10.0 mmHg (range: 1– 16), the cardiac output (CO) of 5.1 L/min (range: 1.3–10.9), and pulmonary vascular resistance of 8.4 Wood Units (range: 2–21). The average of baseline 6MWT was 336 meters (range: 10–930) and mean NT-proBNP was 978.6 ng/L (range: 18-11006). Based on the REVEAL 2.0 or Lite 2 risk scores (mean: 7, range: 2–14), the cohort was categorized at intermediate risk. A total of 71 (55%) patients completed at least 12 months of follow-up. Only five adverse events were reported as possibly related to the CardioMEMS implant procedure, including one serious adverse event. No unexpected adverse events, CardioMEMS device- or system-related adverse events, or sensor failures were reported by study sites throughout each study. Conclusions: The use of CardioMEMS in this combined PAH cohort has demonstrated a favorable safety profile, with few procedure-related adverse events and no enduring consequences. Future studies are warranted to investigate its long-term safety and efficacy in this population.
Heart failure (HF) is associated with considerable morbidity and mortality. The increasing prevalence of HF and inpatient HF hospitalization has a considerable burden on healthcare cost and utilization. The recognition that hemodynamic changes in pulmonary artery pressure (PAP) and left atrial pressure precede the signs and symptoms of HF has led to interest in hemodynamic guided HF therapy as an approach to allow earlier intervention during a heart failure decompensation. Remote patient monitoring (RPM) utilizing telecommunication, cardiac implantable electronic device parameters and implantable hemodynamic monitors (IHM) have largely failed to demonstrate favorable outcomes in multicenter trials. However, one positive randomized clinical trial testing the CardioMEMS device (followed by Food and Drug Administration approval) has generated renewed interest in PAP monitoring in the HF population to decrease hospitalization and improve quality of life. The COVID-19 pandemic has also stirred a resurgence in the utilization of telehealth to which RPM using IHM may be complementary. The cost effectiveness of these monitors continues to be a matter of debate. Future iterations of devices aim to be smaller, less burdensome for the patient, less dependent on patient compliance, and less cumbersome for health care providers with the integration of artificial intelligence coupled with sophisticated data management and interpretation tools. Currently, use of IHM may be considered in advanced heart failure patients with the support of structured programs.
Heart failure (HF) management guided by hemodynamics obtained from an implantable pulmonary artery pressure (PAP) sensor (CardioMEMS) improves symptoms and reduces HF hospitalizations (HFH). This paper reviews the theoretical basis of pulmonary vascular physiology, summarizes recently published data about CardioMEMS, and provides practical guidelines for patient selection and management. Compared to patients managed by standard care, HF patients randomized to PAP-guided treatment have a higher frequency of medication adjustments, resulting in lower PAP and fewer HFH. Real-world analyses further support associations between implant of the CardioMEMS sensor with reductions in PAP, hospitalizations, and mortality. Implantable, wireless hemodynamic sensor technology is a promising remote monitoring platform for chronic HF. A phased approach using a treatment algorithm may improve the efficiency and effectiveness of pressure-guided therapy.
Introduction: Managing pulmonary hypertension (PH) and limiting the progression of pulmonary vascular disease in patients with restrictive cardiomyopathy (RCM) is vital to preserving their candidacy for heart transplant. CardioMEMS TM HF (Abbott Laboratories), an implantable pulmonary artery (PA) pressure sensor, may improve outcomes in these patients through real-time, invasive hemodynamic monitoring to inform titration of PH therapy. We present the first case of a CardioMEMS TM HF implant in a pediatric patient with PH secondary to RCM on mechanical circulatory support. Patient Information: A 9-year-old girl with a history of restrictive cardiomyopathy, previously managed with percutaneous atrial septal fenestration and home milrinone infusion, presented with frequent episodes of syncope. Clinical Findings: Her exam and data were notable for mild tachypnea and hepatomegaly with preserved end-organ function. Echocardiogram disclosed grade 2 diastolic dysfunction and a TAPSE of 1.2 cm (Z score = -5.5). Cardiac catheterization demonstrated right ventricular pressure of 103/24 mmHg, mean PA pressure of 70 mmHg, left ventricular end diastolic pressure of 29 mmHg, cardiac index of 2.1 L/min/sqm, and indexed pulmonary vascular resistance (PVRi) of 22 iWU. Diagnostic Assessment & Reasoning: Given her severe combined pre- and post-capillary PH and end-stage RCM, a Berlin Heart EXCOR left ventricular assist device (LVAD) with atrial cannulation was implanted as a bridge to potential heart-only transplant. Given the high-risk hemodynamics, intravenous treprostinil was initiated in the operating room and subsequently up titrated with close observation for side-effects. Therapeutic Intervention(s) and Timeline: Five months after LVAD implant, cardiac catheterization on treprostinil 60 ng/kg/min and enteral sildenafil and ambrisentan demonstrated PVRi acceptable for heart transplant. A CardioMEMS TM HF device was implanted in the distal left pulmonary artery without incident to record daily PA pressures and inform continued use of PH therapies while awaiting transplant. One month later, the patient underwent successful heart transplantation. Follow-up, Outcomes & Adverse Events: Treprostinil was discontinued shortly after transplant due to bleeding. CardioMEMS TM HF data enabled precise titration of pulmonary vasodilator therapies in the step-down unit. Four-week post-transplant catheterization on sildenafil monotherapy demonstrated improving PH with mean PA pressure of 28 mmHg and PVRi of 3.5 iWU. Discussion & Synthesis: CardioMEMS TM HF provided hemodynamic data enabling inpatient PH medication titration in a child with RCM on LVAD. Use of the device was safe, feasible and informed clinical management. Pediatric patients on advanced cardiac therapies, especially those with combined pre- and post-capillary PH, may benefit from CardioMEMS TM HF while awaiting transplant.
In the left ventricular assist device (LVAD) population, right ventricular (RV) failure represents a significant cause of morbidity and mortality. It is unclear whether hemodynamic monitoring with the implantable CardioMEMS system can improve outcomes within this population. This case report highlights two patients in our clinic who had CardioMEMS implanted after LVAD, enabling us to modify their medical regimens remotely and more frequently in the management of their RV failure.
No abstract available
No abstract available
No abstract available
No abstract available
Background & objectives: Reusable biostrip consisting enzymes immobilized onto alkylamine glass beads affixed on plasticized PVC strip for determination of triglyceride (TG) suffers from high cost of beads and their detachments during washings for reuse, leading to loss of activity. The purpose of this study was to develop a cheaper and stable biostrip for investigation of TG levels in serum. Methods: A reusable enzyme-strip was prepared for TG determination by co-immobilizing lipase, glycerol kinase (GK), glycerol-3-phosphate oxidase (GPO) and peroxidase (HRP) directly onto plasticized polyvinyl chloride (PVC) strip through glutaraldehyde coupling. The method was evaluated by studying its recovery, precision and reusability. Results: The enzyme-strip showed optimum activity at pH 7.0, 35°C and a linear relationship between its activity and triolein concentration in the range 0.1 to 15 mM. The strip was used for determination of serum TG. The detection limit of the method was 0.1 mM. Analytical recovery of added triolein was 96 per cent. Within and between batch coefficients of variation (CV) were 2.2 and 3.7 per cent, respectively. A good correlation (r=0.99) was found between TG values by standard enzymic colrimetric method employing free enzymes and the present method. The strip lost 50 per cent of its initial activity after its 200 uses during the span of 100 days, when stored at 4°C. Interpretation & conclusions: The nitrating acidic treatment of plasticized PVC strip led to glutaraldehyde coupling of four enzymes used for enzymic colourimetric determination of serum TG. The strip provided 200 reuses of enzymes with only 50 per cent loss of its initial activity. The method could be used for preparation of other enzyme strips also.
No abstract available
Lipoprotein lipase (LPL) is an essential enzyme that hydrolyzes triglycerides in chylomicrons and very low-density lipoprotein into glycerol and fatty acids. One major hurdle in using LPL as a therapeutic has been its poor solubility/stability after purification. Solutions used to preserve purified LPL commonly contain either heparin, or concentrated glycerol and sodium chloride, resulting in hypertonic solutions. These solutions are not acceptable as pharmaceutical formulations. This paper describes the identification of a key excipient, sodium laurate, which can solubilize LPL in an isotonic environment without heparin or concentrated glycerol. A follow-up multi-variant study was performed to identify the effect of sodium laurate and its interaction with sodium chloride on the solubility and processing conditions of LPL. The LPL concentration (up to 14 mg/mL) achievable in pharmaceutically relevant and salt-free conditions was identified to be closely correlated to the concentration of sodium laurate, which was co-concentrated with LPL. The results that sodium laurate increases stability of LPL characterized by differential scanning calorimetry and UV absorbance spectra suggests that the mechanism of solubilization of LPL by sodium laurate is related to LPL structural stabilization. The findings indicate that substrates and their enzymatic products can be strong stabilizers for other protein molecules.
Polyelectrolyte-doped microcapsules (PDM) was fabricated by coaxial electrospray of a mixture of glycerol and water containing 10 mg/mL cationic polyelectrolyte poly(allylamine hydrochloride) (PAH) fed as the core phase solution, and a N,N-dimethylacetylamide solution of 10 wt% polyurethane fed as the shell phase solution. Multi-enzyme system involving Candida Antarctica lipase B (CALB), glucose oxidase (GOD), and horseradish peroxidase (HRP) for cascade reaction was assembled in the PDM at three different places, namely, surface, shell, and lumen. Placing of enzyme inside aqueous lumen of the PDM was realized by in situ encapsulation through adding the enzyme in the core-phase solution for coaxial electrospray. By ion-pairing of enzyme with cationic surfactant CTAB, an organic soluble enzyme-CTAB complex was prepared, so that in situ embedding of enzyme in the shell of the PDM was realized by adding it into the shell phase solution. Surface attachment of enzymes was achieved by layer-by-layer (LbL) technology, which is based on the ion-exchange interactions between oppositely charged enzymes and PAH that was doped in PDM. The enzyme-decorated microcapsule was then studied as a micro-bioreactor, in which 1-Oxododecyla-α-glucopyranoside was converted by CALB to glucose, which was oxidised by GOD to gluconolactone in a second step. The hydrogen peroxide produced was then used by HRP to oxidize ABTS to form coloured radical cation ABTS•+ for activity analysis. The successful fabrication of the PDM and precise localization of enzymes in the PDM by different strategies were fully characterized. By varying the immobilization strategy, totally six PDM bioreactors with three enzymes precisely positional assembled in different strategies were constructed and their activities for the cascade reaction were investigated and compared. The PDM micro-bioreactor prepared by novel electrospray technologies provide a smart platform for positional assembly of multi-enzyme cascade reaction in a precise and well-controlled manner.
An enhanced amperometric triglyceride (TG) biosensor was created by electrodepositing graphene oxide nanoparticles (GrONPs) onto pencil graphite electrode (PGE) and then co-immobilizing enzyme nanoparticles (ENPs) of lipase, glycerol kinase nanoparticles (GKNPs), and glycerol 3-oxidase (GPONPs), onto this modified electrode. Electrochemical impedance spectroscopy (EIS), cyclic voltammetry, and scanning electron microscopy (SEM) were employed to examine the working electrode (ENPs/GrONPs/PGE) at various phases of its creation. At an applied potential of 0.3V, the biosensor showed its best current response within- 2s. The electrode's ideal pH and temperature were 7.5 and 40˚C, and its linearity was seen for triolein in the concentration range of 0.01 to 60 mM, with a detection limit (LOD) of 0.2 nM. In human serum, the biosensor showed an analytical recovery of 98% for added triolein. The coefficients of variability both within and between batches were 0.048% and 0.05%, respectively. The TG levels in sera as determined by the current biosensor and the conventional enzymic colorimetric technique showed a significant correlation (R2 = 0.99). This biosensor measured the levels of TG in the serum of patients with cardiogenic shock and hyperlipidemia as well as those who appeared to be in apparently healthy condition. The storage stability of electrode revealed only 25% decrease in its initial activity of the electrode, after its regular uses for 240 days of storage in dry condition at 4˚C. Int. J. Appl. Sci. Biotechnol. Vol 13(1): 1-11. Graphical Abstract: Construction of triglyceride biosensor based on LipaseNP/GKNPs/GPONPs/GONS/PGE.
No abstract available
Silk‐fibroin is utilized as a biocompatible and bioresorbable enzyme immobilization matrix and exemplarily demonstrated for a screen‐printed amperometric glucose biosensor. The silk‐fibroin is derived from the silkworm Bombyx mori. The enzyme immobilization matrix consisting of silk‐fibroin, together with glucose oxidase from Aspergillus niger, is applied to a screen‐printed carbon‐based, biocompatible, and biodegradable working electrode on a flexible silk‐fibroin substrate. The biosensor is characterized electrochemically at physiological glucose concentrations in the range from 0.5 to 10 mm. The results are compared to a “conventional” glucose biosensor, also fabricated on a flexible silk‐fibroin substrate, however utilizing a laboratory standard enzyme immobilization matrix based on bovine serum albumin and glutaraldehyde. Furthermore, the influence of pH (pH 5.5 to pH 8.0) and temperature variations (21 to 70 °C) on these two different immobilization matrices are studied.
No abstract available
Pure silk fibroin (SF) hydrogel exhibits poor elasticity and low water retention ability, owing to the compact crystalline structure and high content of hydrophobic amino acids. Herein, a composite double-network hydrogel of SF and tyramine-modified hyaluronic acid (mHA) was constructed, via the laccase-catalyzed coupling reactions between the phenolic hydroxyl groups from SF and mHA chains. The obtained hydrogel exhibits improved structural stability and flexibility compared to pure SF hydrogel. Meanwhile, the swelling ratio, mechanical property, drug loading, and release behaviors can be readily regulated by alcoholization, altering pH value, and ionic strength of soaking solutions. Increasing pH values promoted the swelling capacity of SF/mHA hydrogel, resulting in an efficient loading of cationic drugs and sustained release of anionic drugs as well. The addition of inorganic salts reduced electrostatic repulsion in the hydrogel scaffold, accompanying with a noticeable improvement of toughness. Furthermore, alcohol treatment induced conformation changes of fibroin protein, and the composite hydrogel achieved a higher fracture and improved elasticity. The present work provides a biological alternative to regulate the mechanical behavior, drug loading, and sustained release capacity of the SF-based hydrogel.
Azo dyes in textile industry effluents pose significant health and environmental risks. Laccase is an enzyme capable of degrading azo dyes, offering an environmentally friendly solution for treating textile wastewater. However, laccases need to be immobilized on specific carriers to enable effective reuse in batch reactors and continuous operation in flow-through reactors. This study employed silk fibroin nanofibers (SFNFs) obtained by mechanically grinding degummed silkworm silk as sustainable carriers to immobilize laccases through carbodiimide-mediated crosslinking. The immobilized laccases (SFNF-laccases) exhibited improved pH tolerance in the range of pH 3.0-8.0 with a smaller change in activity compared to free laccases (SFNF-laccases: 32.9 %, free laccases: 50.4 %). The thermal stability of immobilized laccases was also improved, showing 19, 13, and 9 % higher activities than those of free laccases at 40, 50, and 60 °C, respectively. After 8 days of storage, the activity of SFNF-laccases was 79 % of their activity immediately after immobilization, whereas free laccases retained only 29 % of their initial activity. In addition, SFNF-laccases maintained 73 % of their original operational activity in a flow-through reactor after 8 days. These results demonstrate the great potential of mechanically ground SFNFs as carriers of laccase and the resulting SFNF-laccases in industrial wastewater treatment.
Silk fibroin self‐assembly is introduced as a fully aqueous, solvent‐ and cross‐linker‐free strategy for noncovalent multienzyme coimmobilization. Salt‐driven structuring enables simultaneous enzyme entrapment within a shared protein matrix, while modulation of ionic strength allows controlled enzyme incorporation and adjustment of cascade stoichiometry. Using the alanine dehydrogenase/formate dehydrogenase redox cascade for l ‐norvaline synthesis as a model system, co‐entrapment within the fibroin matrix enhances operational robustness, sustaining 200 h of cumulative batch operation and achieving a cumulative catalytic turnover exceeding 9000 mol l ‐norvaline per mol of alanine dehydrogenase under the tested conditions. Structural characterization reveals an interconnected microglobular architecture consistent with a confined protein‐based microenvironment capable of influencing diffusion–reaction coupling. Competitive assays indicate reduced NADH accessibility in the coassembled system, consistent with partial cofactor confinement. Extension to additional reductase/glucose dehydrogenase cascades demonstrates compatibility across distinct enzyme classes and reveals substrate‐dependent effects linked to diffusion dynamics and matrix–substrate interactions. Collectively, these results establish salt‐assembled silk fibroin as an active protein matrix that stabilizes multienzyme systems while modulating cofactor accessibility and substrate distribution without covalent modification.
Front-end monitoring of coupling and load conditions is vital for next-generation inductive power transfer (IPT) systems, especially with the shift to new control paradigms. Existing monitoring schemes often face challenges such as non-resonant frequency identification, low accuracy, extensive data measurement requirements, and limited operating conditions. To tackle these issues, this paper proposes a resonant-frequency-based dynamic front-end monitoring strategy for typical series-series (SS)-compensated IPT systems. This method is grounded in the small-signal model of the SS-compensated IPT system, allowing for the estimation of mutual inductance and load conditions based solely on the dynamic responses of the transmitter-side current, without requiring communication feedback from the receiver. A key advantage of this strategy is its ability to accurately and rapidly determine mutual inductance and load conditions at resonant frequency during the initial soft starting phase. Both simulation and experimental results demonstrate the superior performance of the proposed monitoring strategy compared to conventional non-resonant frequency-based steady-state methods.
No abstract available
No abstract available
This paper presents the design and optimization of a Class-E-based adaptive binary phase-shift keying (A-BPSK) wireless power and data transmission (WPDT) system operating through a near-field inductive link. The system model incorporates both power transfer and data modulation paths, and the effect of resonant network parameters on phase transition and demodulation is systematically analyzed. A complete design methodology is developed, which for the first time provides a quantitative determination of the RX parallel capacitor CR to balance demodulation stability and transient settling speed. Furthermore, a 20-phase voltage-controlled oscillator (VCO)–based phase-selection scheme is proposed to choose the optimal reference phase for downlink demodulation, thereby enhancing timing alignment and robustness. The proposed optimization achieves stable zero-voltage switching (ZVS) operation and reliable data recovery. Measurement results under 13.56 MHz carrier frequency demonstrate successful demodulation of pseudo-random binary sequences with an averaged data rate of 6.02 Mbps and a bit-error rate below 10−6.
Silicon carbide (SiC) has been extensively investigated in the last decade, specifically for applications in harsh environments. However, most SiC sensors require an external power supply, which cannot operate at high temperatures. This letter develops a new sensing technology in a SiC platform based on near field communication to eliminate the requirement for wired power sources. The 3C-SiC temperature sensors were fabricated from a SiC-on-insulator substrate formed by anodic bonding. The sensors functioned based on the thermoresistance of the SiC films with the high TCR of −13 000 ppm/K at 300 K and −3 000 ppm/K at 600 K. The resistance change of the sensors was wirelessly measured using a reading coil placed outside of the heating chamber, showing a significant resonant-frequency-shift (−400 ppm/K at 600 K) of the coupling impedance under temperature variation. The proposed technique is promising for the development of wireless wide-band-gap sensors used in extreme conditions.
Intermediate resonators (repeaters) of resonant inductive coupling wireless power transfer systems can improve the transmission distance as well as the output power. However, frequency bandwidths in which the repeater can operate effectively are very narrow because the repeater usually has a high quality-factor. Furthermore, these frequency bandwidths shift for the following two factors. The first factor is the intensity of the magnetic coupling between the repeater and the other resonator. The second factor is the variation in the natural resonance frequency of the resonators due to a production error, temperature characteristic, and aging degradation. Therefore, the repeater is not practical because the repeater requires accurate adjusting of the circuit parameters every time according to the various conditions. To address this problem, we propose an impedance matching method for the repeater. The proposed method can maximize the induced current in the repeater in wide frequency bandwidth regardless of the variations in the intensity of the magnetic coupling and the natural resonance frequency. Therefore, the proposed method can realize the repeater which can stably improve the performance of the wireless power transfer. Experiment and simulation successfully verified the effectiveness of the proposed method as well as the appropriateness of the theoretical analysis.
No abstract available
Continuous and non-invasive intraocular pressure (IOP) monitoring is crucial for managing glaucoma, a leading cause of irreversible blindness worldwide. However, existing tonometry methods are intermittent and lack the capability to capture dynamic IOP fluctuations. Herein, we present a highly sensitive, wireless contact lens (WCL) sensor based on a dual-spiral inductor-capacitor-resistor (LCR) resonator for real-time IOP monitoring. The sensor features an axisymmetric anti-parallel spiral architecture that synergistically enhances capacitive coupling and suppresses inductive mutual coupling, thereby amplifying the resonant frequency shift in response to corneal biomechanical deformation. Furthermore, a gradient line-width strategy is implemented to minimize resistive loss, concentrate charge density, and improve mechanical robustness. Systematic evaluations on a biomimetic eyeball platform and ex vivo porcine eyes demonstrate high sensitivity, with values of -1.839 MHz mmHg-1 and -0.69 MHz mmHg-1, respectively. These results highlight the potential of the WCL as a robust and scalable platform for continuous, non-invasive IOP monitoring in glaucoma management.
Pressure is a key unit of measure in aerospace industries. Spontaneous precise measurement of pressure has to be compassed at locations where it is futile and impractical to couple the pressure responsive constituent to the conditional electronics or computational circuit by practicing standard cables and measurements prone to harsh environment. This paper introduces the design of a wireless pressure-monitoring system for aerospace applications in harsh environment. Traditionally, applied pressure deflects a delicate silicon diaphragm, altering the capacitance developed between it and metal electrode firm on a substrate. The LC circuit translates the pressure variation into the LC resonant frequency shift. This change is sensed remotely by virtue of inductance coupling, expelling the compulsion for wire connection rooted telemetry circuits. Novelty of our work rests in the fact that contrary to examining shift in the resonant frequency due to the applied pressure, we have put in effort to maintain resonant shifting equal to zero by varying the capacitance at the observer unit. This will allow pressure variations to be measured directly in terms of the capacitance variation at a fixed resonant frequency, which is 7.92 MHz in our context. According to the application domain (avionics), the proposed sensor structure is designed for functioning in the pressure range between (100 and 1140) mbar. The choice of design values for sensor parameters has been validated. The sensitivity is measured to be 1.746e−17 F/Pa over specified linear range which is shown to match a theoretical estimate realized by mathematical model. An in-depth, step by step derivation of performance parameters to achieve above-stated objective is shown for sensor under study. The results generated are modelled and examined using MATLAB. The analysis conducted dovetail perfectly with the modelled results.
Implantable or subcutaneous biosensors used for continuous health monitoring have a limited functional lifetime which requires frequent replacement and therefore may be highly discomforting to the patient and become costly. One possible solution to this problem is the use of biosensor arrays where each individual reserve sensor can be activated on-demand when the previous one becomes inoperative due to biofouling or enzyme degradation. Each reserve biosensor in the array is housed in an individiual Polydimethylsiloxane (PDMS) well and is protected from exposure to bodily fluids such a s interstitial fluid (ISF) by a thin-film nitrocellulose me mbrane. Controlled activation is achieved by decomposing over an individual sensor well. Electrically activated decomposition of the nitrocellulose membrane is caused by passing an electric current through a Au/Ti filament placed on top of the membrane. By applyingan energy of 7 mJ to the Au/Ti filament with cross-sectional area of $8\times 10^{7}\mathrm{cm}^{2}$, a current density of ≈ 105–106 A/cm2 causes explosive decomposition of thin-film Au. Having a thermal decomposition temperature of ≈ 200°C, nitrocellulose is locally heated directly under the Au/Ti filament. This leads to opening of the nitrocellulose membrane allowing for exposure of biosensor to the biofluid.
Traditional alcohol studies measure blood alcohol concentration to elucidate the biomedical factors that contribute to alcohol abuse and alcoholism. These measurements require large and expensive equipment, are labor intensive, and are disruptive to the subject. To alleviate these problems, we have developed an implantable, wireless biosensor that is capable of measuring alcohol levels for up to six weeks. Ethanol levels were measured in vivo in the interstitial fluid of a Wistar rat after administering 1 g/kg and 2 g/kg ethanol by intraperitoneal (IP) injection. The data were transmitted wirelessly using a biosensor selective for alcohol detection. A low-power piezoresistive microcantilever sensor array was used with a polymer coating suitable for measuring ethanol concentrations at 100% humidity over several hours. A hydrophobic, vapor permeable nanopore membrane was used to screen liquid and ions while allowing vapor to pass to the sensor from the subcutaneous interstitial fluid.
The detection of biomarkers in interstitial fluid (ISF) holds significant promise for early disease diagnosis and monitoring. Porous silicon (pSi) offers a versatile platform for implantable biosensors due to its biocompatibility, high surface area, and tunable properties. This study presents the development and characterization of a label‐free pSi biosensor featuring a near‐infrared (NIR) photonic microcavity (MC) that is implanted subcutaneously in a euthanized mouse to detect insulin in real time for proof of concept. The biosensor demonstrates specific insulin detection ability with a limit of detection (LOD) of 209 nM, exhibiting excellent consistency, reproducibility, and long‐term sensing performance. Furthermore, the biosensor demonstrates the capability to detect insulin spiked into plasma obtained from a healthy mouse. It is further reported that a simple and sensitive data analysis method, the effective shift in wavelength (ESW) method for measuring the shift in center wavelength of the photonic MC. This viable approach can be extended to other photonic biosensors where measurements are limited by the resolution of the spectrometer. The proposed approach lays the foundation for the development of pSi‐based implantable biosensors for real‐time continuous monitoring of clinically relevant biomarkers in vivo for chronic disease management.
Lactate is a key biomarker of tissue metabolism and oxygenation, yet clinical assessment still relies on intermittent blood tests that overlook rapid metabolic dynamics and disrupt clinical workflows. Continuous transdermal monitoring of lactate in interstitial fluid (ISF) offers a minimally invasive approach for real-time monitoring of metabolic status, particularly in conditions associated with metabolic syndrome such as obesity and diabetes. Here we report a proof-of-concept transdermal lactate biosensor based on a fenestrated microneedle array (F-MNA), consisting of a polymeric MNA enclosed within a fenestrated polymeric shell that protects the biosensing layer while retaining access to ISF. Under controlled anesthetized conditions, the biosensor differentiated ISF lactate profiles between healthy and diabetic-obese (db/db) mice, with the db/db group exhibiting higher baseline lactate concentrations. In fasted healthy mice subjected to subcutaneous glucose challenge, the biosensor captured transient increases in ISF lactate followed by partial recovery over the 2 h monitoring period. Biosensor-derived ISF lactate showed strong temporal association with paired blood lactate measurements while exhibiting a systematic positive ISF-to-blood concentration offset. These findings establish proof-of-concept continuous transdermal ISF lactate monitoring under controlled in vivo conditions.
Lactate electrochemical biosensors were fabricated using Pediococcus sp lactate oxidase (E.C. 1.1.3.2), an external polyurethane membrane laminate diffusion barrier and an internal ionomeric polymer barrier (sulphonated polyether ether sulphone polyether sulphone, SPEES PES). In a needle embodiment, a Pt wire working electrode was retained within stainless steel tubing serving as pseudoreference. The construct gave linearity to at least 25 mM lactate with 0.17 nA/mM lactate sensitivity. A low permeability inner membrane was also unexpectedly able to increase linearity. Responses were oxygen dependent at pO2 < 70 mmHg, irrespective of the inclusion of an external diffusion barrier membrane. Subcutaneous tissue was monitored in Sprague Dawley rats, and saliva and sweat during exercise in human subjects. The tissue sensors registered no response to intravenous Na lactate, indicating a blood-tissue lactate barrier. Salivary lactate allowed tracking of blood lactate during exercise, but lactate levels were substantially lower than those in blood (0–3.5 mM vs. 1.6–12.1 mM), with variable degrees of lactate partitioning from blood, evident both between subjects and at different exercise time points. Sweat lactate during exercise measured up to 23 mM but showed highly inconsistent change as exercise progressed. We conclude that neither tissue interstitial fluid nor sweat are usable as surrogates for blood lactate, and that major reappraisal of lactate sensor use is indicated for any extravascular monitoring strategy for lactate.
No abstract available
Electrochemical aptamer-based (EAB) sensors enable high-frequency, real-time measurements of drug concentrations in situ in the body, offering a potential means of rendering therapeutic drug monitoring (TDM) as convenient, timely, and precise as the continuous glucose monitor has rendered the measurement of blood sugar. Fully realizing this vision, however, will require improved understanding of the relationship between drug concentrations in the interstitial fluid (ISF) and in the plasma, as the latter are the basis of nearly all clinical decision-making. Toward this end, here we have used an EAB sensor against the chemotherapeutic methotrexate, a drug that requires monitoring to optimize efficacy and minimize toxicity, to perform simultaneous, seconds-resolved concentration measurements in the plasma and subcutaneous ISF of live rats. Noncompartmental analysis reveals that, while body-mass-adjusted dose is a poor predictor of methotrexate exposure (as area under the curve) in either bodily compartment (R 2 ≤ 0.35), exposure in the ISF strongly predicts plasma exposure (R 2 = 0.85, p = 0.00002). The latter, predictive relationship is sufficiently strong that dosing guided by minimally invasive ISF measurements is twice as accurate as body-mass adjusted dosing at achieving a desired systemic methotrexate exposure. Leveraging the high temporal density of these paired data sets, we also applied compartmental modeling to characterize methotrexate transport between plasma and tissues. Across all 12 paired data sets, the preferred model is a two-compartment differential transport model that allows for asymmetric exchange between plasma and the ISF, providing a significantly more accurate description of the observed kinetics than simple passive diffusion.
Congestive heart failure (CHF) is a fatal disease with progressive severity and no cure; the heart’s inability to adequately pump blood leads to fluid accumulation and frequent hospital readmissions after initial treatments. Therefore, it is imperative to continuously monitor CHF patients during its early stages to slow its progression and enable timely medical interventions for optimal treatment. An increase in interstitial fluid pressure (IFP) is indicative of acute CHF exacerbation, making IFP a viable biomarker for predicting upcoming CHF if continuously monitored. In this paper, we present an inductor-capacitor (LC) sensor for subcutaneous wireless and continuous IFP monitoring. The sensor is composed of inexpensive planar copper coils defined by a simple craft cutter, which serves as both the inductor and capacitor. Because of its sensing mechanism, the sensor does not require batteries and can wirelessly transmit pressure information. The sensor has a low-profile form factor for subcutaneous implantation and can communicate with a readout device through 4 layers of skin (12.7 mm thick in total). With a soft silicone rubber as the dielectric material between the copper coils, the sensor demonstrates an average sensitivity as high as –8.03 MHz/mmHg during in vitro simulations.
Heart failure (HF) induces fluid interstitial retention, leading to oedema and elevated interstitial fluid pressure (IFP).1-3 There is a clinical need for remotely assessing IFP and understanding its correlation with cardiopulmonary haemodynamics for early treatment optimization in HF. IFP can be measured from a preserved fluid pocket formed by a subcutaneous perforated capsule in animals.4 However, the structural understanding of tissue neovascularization within a perforated capsule and the temporal relationship between altered cardiopulmonary haemodynamics and IFP remains unknown. To determine the neovascularisation of the perforated capsule over time and demonstrate the relationship between haemodynamic metrics of congestion (CVP, PAP, and LVEDP) and IFP during HF development. Ten 45-55kg swine were implanted with subcutaneous perforated capsules. Perforated capsule characterisation included MicroCT using MicroFil cast (Fig. 1A) and microscopy initially at 3 and 6 weeks. A perforated capsule containing a PTFE (polytetrafluoroethylene) membrane was subcutaneously implanted in animals and chronic stability was studied at 90 using MicroCT and microscopy. After 3 weeks of perforated capsule implantation, HF was induced under general anaesthesia with 12-16 mg/kg/hour of esmolol (i.v.) and 0.9% NaCl (10% body weight, i.v.) and fluid was removed to euvolemia via ultrafiltration (Fig 2A). Concurrent measurements of IFP from perforated capsules and haemodynamic metrics of congestion were made using interventional techniques. MicroCT and microscopy have demonstrated perforated capsule neovascularization containing a central fluid pocket at 3 weeks and loss at 6 weeks due to continued tissue growth (Fig 1B-E). The perforated capsule at 90 days demonstrated fluid pocket preservation due to the PTFE membrane on MicroCT and microscopy (Fig. 1F-G). During the development of HF and offloading, there is a strong correlation between IFP and haemodynamic metrics of congestion (Fig. 2B). We have developed a minimally invasive technique for continuous IFP measurement demonstrating a relationship between IFP and cardiac filling pressure in HF. IFP assessment offers a direct measure of fluid status and an indirect measure of haemodynamics, facilitating early treatment optimisation.
Microneedle electrochemical biosensors have emerged as a crucial technology for non‐invasive biomarker detection, offering minimally invasive and real‐time monitoring capabilities. These biosensors utilize a microneedle array to extract interstitial fluid, and integrate biological recognition elements (e.g., enzymes, antibodies) and electrochemical signal converters (e.g., current, resistance) to enable rapid and sensitive detection of various biomarkers like blood glucose, lactic acid, and electrolytes. Despite the commercialization of this technology in continuous blood glucose monitoring, challenges persist, including the need to balance needle length and mechanical strength, ensure long‐term stability against biological contamination and enzyme inactivation, and optimize large‐scale manufacturing processes. Future advancements are anticipated through interdisciplinary collaborations, leveraging artificial intelligence for data analysis and exploring biodegradable materials, to facilitate the transition of microneedle electrochemical sensors from research settings to clinical use and advance the field of personalized medicine. This review examines the historical development, design, manufacturing processes, sensing mechanisms, biomarker detection capabilities, and integration potential of microneedle electrochemical biosensors, while also addressing their application prospects and technical hurdles. In 1998, Mark R. Prausnitz's team at the Georgia Institute of Technology first pioneered the use of microneedle arrays for transdermal drug delivery, establishing the groundwork for the application of this technology in the field.[1] Subsequently, in 2004, E.V. Mukerjee's team conducted the first comprehensive investigation into microneedle arrays for percutaneous interstitial fluid (ISF) extraction and in‐situ analysis, opening up a new avenue for biofluid extraction and analysis.[2] In 2010, Mark A. F. Kendall's team introduced a surface‐modified micro‐projection array for direct capture of disease‐specific biomarkers from the skin dermis for detection. Joseph Wang and Roger Narayan's team is dedicated to advancing the practical application of microneedle electrochemical biosensors in personal health monitoring and medical integrating devices through minimally invasive or non‐invasive monitoring of various biomarkers.[3‐5] In 2022, a microneedle‐based electrochemical biosensor was proposed by Sam Emaminejad's team for continuous and real‐time monitoring of drug pharmacokinetics.[6] In 2024, Kelley and colleagues first developed an implantable biosensor utilizing active reset technology for continuous, real‐time monitoring of protein biomarkers in live animals, enabling rapid protein dissociation via high‐frequency oscillation for real‐time monitoring. Meanwhile, Shi et al. proposed a hydrogel‐based one‐component organic electronic device for closed‐loop antiepileptic therapy, integrating electrical recording and drug release functions to predict pathological conditions.[7]
Current implantable sensors are invasive, form fibrotic capsules, and are susceptible to a disconnection between the sensor and the controller. Here, we have developed an implantable wireless glucose monitoring system. This device is composed of an external controller to serve as a human-system interface and an implantable sensor to electrochemically measure glucose levels. Communication between the controller and the sensor is through a pair of an antenna (or coils) using peer-to-peer radio frequency (RF) technology. In addition, the implant’s power is supplied by the controller through RF coupling. Wireless RF technology allows the controller to issue commands to the implant while receiving signals from the sensor. For implantation into rats, the entire implant unit was sealed with polydimethylsiloxane. The working electrodes were modified with various thermoplastic polyurethane (TPU) concentrations for glucose oxidase (GOx) immobilization and evaluated for protein adsorption in a simulated interstitial fluid environment by AUTOLAB. Results indicated that 30 mg/mL of TPU reduced protein adsorption most effectively. To evaluate the signal detection resolution, the device measured hydrogen peroxide levels and compared the data with AUTOLAB. Results indicate that the resolutions of our developed system and AUTOLAB were 114 and < 9.7 nA, respectively. The glucose biosensor with the TPU membrane was subsequently implanted in normoglycemic and hyperglycemic rats. The signal responses obtained from the study rats’ ISF exhibited a significant difference when the blood glucose level changed. A comparison of intravenous and ISF glucose levels revealed a 30 to 170 minutes delay.
No abstract available
Electrochemical aptamer-based (E-AB) sensors can continuously monitor drug concentrations with high temporal resolution. While previous studies have successfully demonstrated in vivo molecular monitoring using E-AB sensors, they typically rely on custom-built probes fabricated through manual, labor-intensive processes. Constructing such probes requires substantial time, technical expertise, and precision, creating a high barrier to entry for researchers interested in the field of in vivo measurements. To address this limitation, we present an alternative fabrication approach that combines established device construction methods with rapid prototyping via additive manufacturing (i.e., stereolithography). This platform enables continuous molecular monitoring in the subcutaneous interstitial fluid (ISF) of rodent models. We selected ISF as a target fluid due to its growing recognition as a promising frontier for continuous molecular monitoring and its central role in current biosensor research. Our goal is to eliminate the most prohibitive steps in traditional fabrication, thereby reducing the skill threshold required for building functional E-AB probes. By improving the construction process, our methods should make the technology more easily adoptable by a broader range of research laboratories. Ultimately, we aim to broaden the use of E-AB sensors and accelerate development in the field of real-time, in vivo molecular monitoring.
Monitoring multiplexed biochemical markers is beneficial for the comprehensive evaluation of diabetes-associated complications. Techniques for multiplexed analyses in interstitial fluids have often been restricted by the difficulties of electrode materials in accurately detecting chemicals in complex subcutaneous spaces. In particular, the signal stability of enzyme-based sensing electrodes often inevitably decreases due to enzyme degradation or interference in vivo. In this study, we developed a self-calibrating multiplexed microneedle (MN) electrode array (SC-MMNEA) capable of continuous, real-time monitoring of multiple types of bioanalytes (glucose, cholesterol, uric acid, lactate, reactive oxygen species [ROSs], Na+, K+, Ca2+, and pH) in the subcutaneous space. Each type of analyte was detected by a discrete MN electrode assembled in an integrated array with single-MN resolution. Moreover, this device utilized an MN-delivery-mediated self-calibration technique to address the inherent problem of decreased accuracy of implantable electrodes caused by long-term tissue variation and enzyme degradation, and this technique might increase the reliability of the MN sensors. Our results indicated that SC-MMNEA could provide real-time monitoring of multiplexed analyte concentrations in a rat model with good accuracy, especially after self-calibration. SC-MMNEA has the advantages of in situ and minimally invasive monitoring of physiological states and the potential to promote wearable devices for long-term monitoring of chemical species in vivo.
In this paper, we have newly designed and fabricated horseshoe-shaped skin attachable minimally invasive wearable patch with implantable microneedle biosensor for continuous glucose monitoring in interstitial fluid (ISF). In order to reduce the effects of skin movement or external stress on the fabricated sensor, we considered both hardness and stretchability of the microneedle and appropriate material. The fabricated microneedle biosensor exhibited an excellent amperometric response to glucose molecules as much as $128.65\ \mu \mathrm{A}/\text{mM}\cdot \text{cm}^{2}$ and ultra-low limit of detection (LOD) as $0.198\ \mu \mathrm{M}$. Furthermore, the linear range of the sensor was indicated up to 30 mM in two glucose concentration regions.
No abstract available
No abstract available
No abstract available
BACKGROUND Hypertriglyceridemia (HTG) is a major cause of acute pancreatitis (AP). We aimed to determine whether HTG is an independent risk factor for AP complications and construct a prediction model for non-mild AP. METHODS We conducted a multi-center cohort study including 872 patients with AP and divided them into HTG-AP and non-HTG-AP groups. Multivariate logistic regression was performed, and a prediction model for non-mild HTG-AP was developed. RESULTS HTG-AP patients had a higher risk of systemic complications, including systemic inflammatory response syndrome [odds ratio (OR): 1.718; 95% confidence interval (CI): 1.286-2.295], shock (OR: 2.103; 95%CI: 1.236-3.578), acute respiratory distress syndrome (OR: 2.231; 95%CI: 1.555-3.200), acute renal failure (OR: 1.593; 95%CI: 1.036-2.450), and local complications such as acute peripancreatic fluid collection (OR: 2.072; 95%CI: 1.550-2.771), acute necrotic collection (OR: 1.996; 95%CI: 1.394-2.856), and walled-off necrosis (OR: 2.157; 95%CI: 1.202-3.870). The area under curve of our prediction model was 0.898 (95%CI: 0.857-0.940) and 0.875 (95%CI: 0.804-0.946) in the derivation and validation datasets respectively. CONCLUSION HTG is an independent risk factor for AP complications. We constructed a simple and accurate prediction model for progression of non-mild AP.